Page last updated: 2024-08-18

pyrroles and pravastatin

pyrroles has been researched along with pravastatin in 488 studies

Research

Studies (488)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	21 (4.30)	18.2507
2000's	370 (75.82)	29.6817
2010's	94 (19.26)	24.3611
2020's	3 (0.61)	2.80

Authors

Authors	Studies
Bak Mueller, S; Bocan, TM; Dehart, P; Ferguson, E; Krause, BR; McNally, W; Newton, RS; Roth, BD; Sliskovic, DR; Uhlendorf, PD	1
Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR	1
Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR	1
Bertolini, S; Bon, GB; Campbell, LM; Egros, F; Farnier, M; Fayyad, R; Langan, J; Mahla, G; Nawrocki, JW; Pauciullo, P; Sirtori, C	1
Roberts, WC	1
Baetta, R; Calore, M; Comparato, C; Donetti, E; Fumagalli, R; Paoletti, R; Rossi, A; Soma, MR; Teruzzi, C	1
Hunninghake, D; Jones, P; Kafonek, S; Laurora, I	1
Lane, M; Laskarzewski, P; Stein, EA	1
Black, DM; Mahla, G; Muller, D; Pentrup, A; Wolffenbuttel, BH	1
Wehmeier, T; Ziajka, PE	1
Pincus, J	1
Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A	1
D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW	1
Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ	1
Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ	1
Blanco-Colio, LM; Egido, J; Guijarro, C; Kasiske, BL; Keane, WF; Massy, ZA; O'Donnell, MP	1
Frohlich, BH; Gregg, RE; Tesfamariam, B	1
Kivistö, KT; Lilja, JJ; Neuvonen, PJ	1
Branchi, A; Fiorenza, AM; Macor, S; Muzio, F; Rovellini, A; Sommariva, D; Torri, A	1
Farnier, M	1
Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A	1
Hecker, M; Just, I; Köhler, T; Rückschloss, U; Wagner, AH	1
Bakker-Arkema, RG; Black, DM; Nawrocki, JW	1
Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I	1
Blair, SN; Capuzzi, DM; Cater, NB; Gottlieb, SO; Morgan, JM; Nguyen, T	1
Branzi, A; Carinci, V; Magelli, C; Magnani, G; Potena, L; Reggiani, LB	1
Dansette, PM; Jaoen, M; Pons, C	1
Huang, J; Kiener, PA; Knapp, AC; Starling, G	1
Brown, WV	1
Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P	1
Cromwell, WC; Ziajka, PE	1
Ose, L; Risberg, K; Svilaas, A; Thoresen, M	1
Kwak, B; Mach, F; Mulhaupt, F; Myit, S	1
Davidson, MH	1
Stein, EA	2
Crouch, MA	1
Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M	1
Jackson, G	2
Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S	1
Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; O'Malley, PG; Taylor, AJ	1
Rosenson, RS; Schaefer, EJ; Tangney, CC	1
Adams-Huet, B; Balis, D; Devaraj, S; Grundy, SM; Jialal, I; Stein, D	1
Hilleman, DE; Lenz, TL; Wurdeman, RL	1
Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK	1
Beinlich, CJ; Ichihara, K; Morgan, HE; Satoh, K; Shirota, F; Tsunajima, T	1
Lupattelli, G; Palumbo, B; Sinzinger, H	1
Maclaine, GD; Patel, H	1
Casciano, CN; Clement, RP; Johnson, WW; Wang, E	1
Anthony, M; Bleske, BE; Casselberry, N; Datwani, M; Secontine, SG; Shea, MJ; Uhley, VE; Willis, RA	1
Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H	1
Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH	1
Auer, J; Eber, B	1
Conradie, MM; Gopal, R; Hough, S; Hulley, PA; Maritz, FJ	1
Igel, M; Sudhop, T; von Bergmann, K	1
Ichihara, K; Kaneta, S; Marumo, H; Satoh, K; Yamamoto, A	1
Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY	1
Bazalo, GR	1
Alfón, J; Badimon, L; Berrozpe, M; Martínez-González, J	1
Hsue, PY; Waters, DD	1
Adams-Huet, B; Balis, D; Devaraj, S; Jialal, I; Stein, DT	1
Altamura, L; Chiariello, L; Crea, F; Gaspardone, A; Gioffrè, PA; Proietti, I; Tomai, F; Versaci, F	1
Berthier, S; Hartmann, S; Hubert, M; Kovarik, JM; Rordorf, C; Rosenkranz, B; Schneider, W	1
Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN	1
Aberg, JA; Alston, B; Aweeka, F; Blaschke, T; Fang, F; Fichtenbaum, CJ; Gerber, JG; Kosel, B; Rosenkranz, SL; Segal, Y	1
Belder, R; Braunwald, E; Breen, J; Cannon, CP; McCabe, CH	1
Athyros, VG; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA	1
Piliero, PJ	1
Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN	1
Auteri, A; Bova, G; Bruni, F; Cercignani, M; Console, E; Palazzuoli, A; Pasqui, AL; Puccetti, L	1
Hinman, J; Scanu, AM	1
Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ	1
Shah, PK	1
Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ; Vernalis, MN	1
SoRelle, R	1
Chmielewski, M; Rutkowski, B; Zdrojewski, Z	1
Blaschke, F; Bokemeyer, J; Fleck, E; Goetze, S; Graf, K; Kappert, K; Kintscher, U; Schmidt, G; Stawowy, P	1
Frolkis, JP; Minor, S; Nambi, V; Pearce, GL; Sprecher, DL	1
Bates, ER; Carville, DG; Guyer, KE; Hopp, AS; Horowitz, K; Lau, WC; Neer, CJ; Tait, AR; Waskell, LA; Watkins, PB	1
Sinzinger, H	1
Angori, P; Auteri, A; Bova, G; Bruni, F; Cercignani, M; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L	1
Derhaschnig, U; Dorner, GT; Jilma, B; Joukhadar, C; Petternel, V; Rassoul, F; Richter, V; Wagner, OF; Wolzt, M	1
Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ	2
Krane, V; Wanner, C	1
Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M	1
Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA	1
Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J	2
Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ	1
Fuller, S; Gillen, D; Lacey, L; Marriott, J; Wilson, K	1
McBurney, CR; Smith, DG	1
Clark, LT	1
Liebson, PR	1
Oguogho, A; Sinzinger, H	1
Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL	1
Sudhop, T; von Bergmann, K	1
Betz, W; Devroey, D; Duquet, W; Velkeniers, B	1
Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA	1
Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA	1
Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Slavina, NN; Vaulin, NA	1
Berkenboom, G; Fontaine, D; Fontaine, J; Otto, A	1
Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR	1
Nasu, M; Tamura, A; Watanabe, T	1
Kent, SM; Taylor, AJ	1
Brown, WV; Moussa, M	1
Ichihara, K; Kanda, M; Satoh, K	1
Gupta, S	1
Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A	1
Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM	1
Aleo, E; Dmitrieva, A; Littarru, GP; Passi, S; Stancato, A	1
Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T	1
Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K	1
Ruef, J	1
März, W	3
Kröger, K; Wittlinger, T	1
Edwards, JE; Moore, RA	1
Einecke, D	4
Cannon, CP	1
Mach, F	1
Brodie, B; Brown, BG; Cooper, CJ; Crowe, T; DeMaria, AN; Ganz, P; Grines, CL; Howard, G; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Vogel, RA	1
Sacks, FM	1
Belder, R; Braunwald, E; Cannon, CP; Hill, KA; Joyal, SV; McCabe, CH; Pfeffer, MA; Rader, DJ; Rouleau, JL; Skene, AM	1
Topol, EJ	1
Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Rodis, FI; Tselepis, AD	1
Fukazawa, I; Uchida, E; Uchida, N; Yasuhara, H	1
Fang, CH; Li, JJ	1
Tellier, P	1
Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG	1
Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C	1
Kulbertus, H; Scheen, AJ	1
Hobbs, RA; Tafreshi, MJ	1
Fujisaki, K; Itoh, Y; Kubota, T; Oishi, R; Sendo, T; Yano, T	1
Salam, AM	1
Nissen, S	1
Bell, PR; Loftus, IM; Molloy, KJ; Naylor, AR; Schwalbe, EC; Thompson, MM	1
van der Harst, P; van Veldhuisen, DJ; Voors, AA	1
Hegmann, T	1
LeLorier, J; Paradis, JM	1
Gotto, AM	2
Miller, M	1
Auer, J; Eber, B; Weber, T	1
Levenson, D	1
von Schacky, C	1
Egido, J; Tuñón, J	1
Jacobson, TA	1
Cannon, CP; Ray, KK	2
Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA	1
Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR	1
Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW	1
Deedwania, PC	1
Braunwald, E; Cannon, CP; McCabe, CH; Morrow, D; Pfeffer, MA; Ridker, PM; Rifai, N; Rose, LM	1
Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM	1
Endo, K; Ito, Y; Koide, N; Miyashita, Y; Otsuka, M; Oyama, T; Ozaki, H; Saiki, A; Shirai, K	1
Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T	1
Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH	1
Isley, WL	1
Fitchett, DH; Goodman, S; Langer, A; Leiter, LA; Tardif, JC	1
Ilkay Alp, F; Kaleli, D; Ozdemir, O; Sönmez Uydeş-Doğan, B; Takir, S; Topal, G	1
Hirsch, M; Jones, P; O'Donnell, JC	1
Cheng, TO	1
Farmer, JA	2
Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L	1
Arimochi, H; Hagiwara, M; Kataoka, K; Kuwahara, T; Nakayama, H; Ohnishi, Y	1
Judge, HM; Peters, G; Smith, SM; Storey, RF	1
Arnaud, C; Burger, F; Mach, F; Nguyen, TH; Steffens, S; Trono, D; Veillard, NR	1
Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C	1
Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z	1
Alsheikh-Ali, AA; Karas, RH	2
Curtiss, FR	1
Bittolo Bon, G; Calabresi, L; Cattin, L; Fellin, R; Manzato, E; Montagnani, M; Pauciullo, P; Pisciotta, L; Sirtori, CR	1
Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S	1
Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR	1
Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA	1
Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM	1
Berna, C; Calmy, A; Junod, AF; Peytremann-Bridevaux, I	1
Jones, P; Miller, PS; Smith, DG	1
Iwano, C; Matsuyama, K; Matzno, S; Nishikata, M; Yasuda, N	1
Cannon, CP; Reid, IR; Tonkin, A	1
Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C	1
Kastelein, JJ; van Leuven, SI	1
Fujita, H; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Murata, I; Okubo, M; Sano, K; Tsuchiya, K; Yokoyama, H; Zhou, X	1
Chiba, K; Hosokawa, M; Kameyama, Y; Kobayashi, K; Yamashita, K	1
Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A	1
Auer, J; Eber, B; Lamm, G	1
Hirose, T; Kawamori, R; Ohmura, C; Tanaka, Y; Watada, H	1
Miyashita, Y; Murano, T; Oyama, T; Saiki, A; Shirai, K; Watanabe, F	1
Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Gustafsson, I; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Stender, S; Torp-Pedersen, C	1
Bergman, M; Bessler, H; Djaldetti, M; Salman, H; Straussberg, R	1
Corpataux, JM; London, NJ; Naik, J; Porter, KE	1
Asberg, A; Hermann, M; Holdaas, H; Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K	1
Cicero, AF; Gaddi, A	1
Boehlen, F; Daali, Y; de Moerloose, P; Fontana, P; Mach, F; Reber, G; Senouf, D; Sigwart, U	1
Damkier, P; Hallas, J; Korsholm, L; Kristensen, SR; Mickley, H; Poulsen, TS; Vinholt, P	1
Austin, PC; Mamdani, MM	1
Nissen, SE	2
Carbonell, T; Freire, E	1
Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR	1
Field, KM	1
Baldassarre, S; Carpentier, YA; Deckelbaum, RJ; Ducobu, J; Dupont, IE; Scruel, O	1
Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT	1
Braunwald, E; Cairns, R; Cannon, CP; Jackson, G; McCabe, CH; Ray, KK; Sacks, FM; Tonkin, AM	1
Braunwald, E; Cannon, CP; Morrow, DA; Pfeffer, MA; Ray, KK; Wiviott, SD	1
Braunwald, E; Cairns, R; Cannon, CP; Gibson, CM; Kirtane, AJ; McCabe, CH; Morrow, DA; Ray, KK; Ridker, PM; Rifai, N; Skene, AM	1
Davidson, M	1
Amarenco, P; Labreuche, J; Lavallée, PC; Touboul, PJ	1
Amyot, R; Arnold, M; Bonafede, N; Cannon, CP; Dupuis, J; Lonn, E; Ricci, J; Rouleau, JL; Roux, R; Tardif, JC; Title, LM; Woo, A	1
Phillips, PS	1
Bergman, M; Bessler, H; Djaldetti, M; Salman, H	3
Ichihara, K; Kanda, M; Kasai, T; Keimatsu, N; Satoh, K; Sun, F; Takaguri, A	1
Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A	1
Fonarow, GC	1
Bots, AF; Kastelein, JJ	1
Rouleau, J	1
Crowe, T; Kapadia, S; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM	1
Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M	1
Graselli, U; Joukhadar, C; Kostner, K; Lackner, E; Thallinger, C; Urbauer, E; Wolzt, M	1
Aldama-López, G; Campo-Pérez, R; Castro-Beiras, A; Crespo-Leiro, MG; Llinares-García, D; Marzoa-Rivas, R; Muñiz-Garcia, J; Paniagua-Marin, MJ; Piñón-Esteban, P	1
Jadhav, SB; Jain, GK	1
Chen, MS; Crowe, T; Kapadia, S; Loyd, AB; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM	1
Crespo, MJ; Quidgley, JA	1
Kilkki, E; Kivistö, KT; Niemi, M; Soininen, K; Strandberg, T	1
Pilote, L; Rahme, E; Zhou, Z	1
Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Koter-Michalak, M	1
Clearfield, M	1
Fukazawa, M; Ishikawa, M; Kubota, T; Moroi, M; Namiki, A; Sugi, K; Yajima, S	1
Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V	1
Rosenson, RS	1
Dincer, I; Erol, C; Ertas, F; Ongun, A; Ozdol, C; Turhan, S	1
Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD	1
Braunwald, E; Cannon, CP; McCabe, CH; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS	1
Demyanets, S; Hohensinner, PJ; Huber, K; Kaun, C; Maurer, G; Pammer, J; Pfaffenberger, S; Rega, G; Wojta, J	1
Brown, BG	1
Foody, JM; Galusha, D; Havranek, EP; Krumholz, HM; Masoudi, FA; Radford, MJ; Rathore, SS	1
Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM	1
Gehr, BT; Porzsolt, F; Weiss, C	1
Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC	1
Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T	1
Hayashi, T; Ka, Y; Kitamura, A; Matsumura, Y; Mori, T; Ohkita, M; Sugii, M; Takaoka, M	1
Braunwald, E; Cannon, CP; Jarolim, P; McCabe, CH; Morrow, DA; Ray, KK; Sabatine, MS; Scirica, BM; Shui, A	1
Dörge, H; Grabedünkel, J; Liakopoulos, OJ; Nagorsnik, U; Schmitto, JD; Schoendube, FA	1
Apperson-Hansen, C; Churchill, T; Crowe, T; Lin, S; Loyd, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wang, C; Wolski, K	1
Plans-Rubió, P	1
Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM	1
Buerke, M; Hennen, R; Keller, A; Müller-Werdan, U; Russ, M; Schmidt, H; Werdan, K	1
Allemann, C; Babiychuk, EB; Draeger, A; Hoppeler, H; Mohaupt, M; Monastyrskaya, K; Savolainen, H	1
Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R	1
Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE	1
Iwashita, M; Kono, S; Sasaki, J	1
Braunwald, E; Giugliano, RP	1
Akers, WS; Steinhubl, SR	1
Poli, A; Pujia, A	1
Davidson, MH; Robinson, JG	1
Carod-Artal, FJ	1
Knopp, RH; Paramsothy, P	1
Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE	1
Alberti, A; Bergamasco, L; Brscic, E; Celeste, A; De Bernardi, A; Formato, L; Fuster, V; Moretti, C; Pucci, A; Sheiban, I; Trevi, G	1
Brecht, K; Kaufmann, P; Krähenbühl, S; Török, M; Waldhauser, KM; Zahno, A	1
Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM	1
Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L	1
Barron, TI; Bennett, K; Feely, J	1
Mistafa, O; Roudier, E; Stenius, U	1
Cannon, CP; Ganz, P; Ray, KK	1
Mason, RP	1
Moriguchi, H; Sato, C; Uemura, T	1
Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L	1
Inoue, N; Ishikawa, M; Kato, T; Motomura, K; Oikawa, S; Okajima, F; Shimano, H; Takahashi, A; Yamada, N	1
Billinger, M; Cook, S; Haeberli, A; Hess, OM; Meier, B; Togni, M; Wenaweser, P; Windecker, S	1
Bairey Merz, CN; Cosin-Aguilar, J; Deedwania, P; Koylan, N; Luo, D; Ouyang, P; Piotrowicz, R; Schenck-Gustafsson, K; Sellier, P; Stein, JH; Stone, PH; Thompson, PL; Tzivoni, D	1
Choudhry, NK; Levin, R; Winkelmayer, WC	1
Abe, M; Hirose, T; Kawamori, R; Mita, T; Nakayama, S; Ogihara, T; Shimizu, T; Uchino, H; Watada, H	1
Broncel, M; Chojnowska-Jezierska, J; Koter-Michalak, M	1
Batt, AM; Bertrand-Thiebault, C; Masson, C; Siest, G; Visvikis-Siest, S	1
Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A	1
Frial, T; Miller, PS; Tran, YB	1
Bennett, MT; Bondy, GP; Johns, KW	1
Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH	1
Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM	1
Chen, C; Lin, J; Smolarek, T; Tremaine, L	1
Iwano, C; Matsuyama, K; Matzno, S; Tomiyama, N; Yasuda, N	1
Bhatt, DL; Brennan, DM; Fox, K; Mak, KH; Saw, J; Steinhubl, SR; Topol, EJ	1
Coleman, CI; Dale, KM; Henyan, NN; Kluger, J; White, CM	1
George, J; Keren, G; Luboshits, G; Mausner-Fainberg, K; Maysel-Auslender, S; Mor, A; Rubinstein, A	1
Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD	1
Averna, MR; Bucciarelli, L; Cefalù, AB; Ciabattoni, G; Davì, G; Davì, V; Ferrante, E; Noto, D; Pettinella, C; Santilli, F	1
Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP	1
Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R	1
Cannon, CP; Kumar, A	1
Midgley, L; O'Regan, DJ; Porter, KE; Turner, NA	1
Eggen, AE; Engeland, A; Furu, K; Hartz, I; Njølstad, I; Sakshaug, S; Skurtveit, S	1
Han, YL; Kang, J; Li, CY; Li, Y; Yan, CH	1
Braunwald, E; Buros, J; Cannon, CP; Croce, K; Gao, H; Healy, AM; Libby, P; McCabe, CH; Morrow, DA; Pradhan, AD; Sabatine, MS; Sakuma, M; Simon, DI; Wang, Y	1
Dal Pan, G; McAdams, M; Staffa, J	1
Shaley, FM	1
Blazing, M; Cannon, CP; Gersh, B; McLean, DS; Ravid, S; Shui, A	1
Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV	1
Braunwald, E; Cannon, CP; Catanese, JJ; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Ranade, K; Rowland, CM; Sabatine, MS; Simonsen, KL; Tong, CH	1
Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW	1
Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM	1
Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK	1
Asberg, A; Gedde-Dahl, A; Hejazifar, S; Hoel, K; Skottheim, IB	1
Kumar, V; Shah, RP; Singh, S	1
Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP	1
Abe, Y; Furukado, S; Hori, M; Hoshi, T; Hougaku, H; Kitagawa, K; Sakaguchi, M; Yamagami, H	1
Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B	1
Avisar, I; Brook, JG; Wolfovitz, E	1
Farmer, JA; Jones, PH	1
Ando, H; Fujimura, A; Kaneko, S; Saito, T; Sugimoto, K; Takamura, T; Tsuruoka, S; Yanagihara, H	1
Burke, A; FitzGerald, GA; Ky, B; Rader, DJ; Szapary, PO; Tadesse, MG; Tsimikas, S; Witztum, JL; Wolfe, ML	1
Gratsianskii, NA; Vaulin, NA	1
Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M	1
Ichihara, K; Itagaki, M; Satoh, K; Takaguri, A; Tokumitsu, Y	1
Doggrell, SA	1
Dimitri, E; Landry, P; Légaré, N; Tessier, S	1
Fildes, JE; Leonard, CT; Mitsidou, A; Rogacev, K; Shaw, SM; Williams, SG; Yonan, N	1
Brener, SJ; Hu, T; Ivanc, TB	1
Xiao, H; Yang, CS	1
Chae, A; Choi, SH; DeMaria, AN; Messig, M; Miller, E; Nissen, SE; Ntanios, F; Tsimikas, S; Witztum, JL	1
Nambi, V; Polsani, VR; Virani, SS	1
Ford, JS; Tayek, JA	1
Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K	1
Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD	1
Elsais, A; Kerty, E; Lund, C	1
Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M	1
Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S	1
Braunwald, E; Cannon, CP; Giraldez, RR; Giugliano, RP; McCabe, CH; Mohanavelu, S; Murphy, SA	1
Bienvenu, AL; Picot, S	1
Gamie, Z; Graham, S; Linder, T; Tang, QO; Tran, GT; Tsialogiannis, E; Tsiridis, E	1
Burke, JP; Dhonnchu, TN; Maher, BM; Soo, A; Watson, RW; Wood, AE	1
Mullangi, R; Srinivas, NR	1
Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA	1
Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T	1
Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D	1
Castro-Beiras, A; Crespo-Leiro, MG; Flores, X; Franco, R; Grille, Z; Marzoa, R; Mosquera, V; Naya, C; Paniagua, MJ; Rodriguez, JA	1
Arora, P; Devereaux, PJ; Mills, EJ; Perri, D; Rachlis, B; Wu, P	1
Fukumoto, Y; Rashid, M; Seto, M; Shimokawa, H; Tawara, S; Yano, K	1
Itoh, T; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y	1
Shen, J; Zhang, Q; Zhang, RY	1
Aliabadi, AZ; Dunkler, D; Grimm, M; Grömmer, M; Mahr, S; Wolner, E; Zimpfer, D; Zuckermann, AO	1
Braunwald, E; Cairns, R; Cannon, CP; Morrow, DA; Ray, KK; Ridker, PM	1
Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S	1
Abel, T; Fehér, J	1
Lüscher, TF	1
Satoh, A; Satoh, M	1
Kapoor, AS; Majumdar, SR; McAlister, FA; Mohamed, R; Norris, CM; Pretorius, V; Ross, DB	1
Alonso, J; Cardier, JE; Ledezma, E; Wittig, O	1
Cannon, CP; Gibson, CM; McCabe, CH; Murphy, SA; Tung, P; Wiviott, SD	1
Itoh, T; Maesawa, C; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y	1
Aizawa, K; Ikeda, U; Izawa, A; Kasai, H; Kashima, Y; Koshikawa, M; Koyama, J; Kumazaki, S; Tomita, T; Tsutsui, H	1
Brown, A; Cannon, CP; Mega, JL; Morrow, DA; Sabatine, MS	1
Boari, B; Manfredini, F; Manfredini, R; Salmi, R	1
Bate, A; Edwards, IR; Hägg, S; Strandell, J	1
Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D	1
Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP	1
Cannon, CP; Gibson, CM; Hochberg, CP; Pride, YB; Sabatine, MS; Sloan, S	1
Crosslin, DR; Ginsburg, GS; Messer, C; Reed, CR; Salisbury, BA; Shah, SH; Voora, D; Zhai, J	1
Arishiro, K; Hanafusa, T; Hoshiga, M; Ishihara, T; Kohbayashi, E; Miyazaki, N; Nakakoji, T; Negoro, N; Okabe, T	1
Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD	1
Han, YL; Jing, QM; Li, Y; Wang, DM; Wang, SL; Wang, ZL; Zhang, ZL	1
Acharjee, S; Cannon, CP; McCabe, C; Murphy, SA; Qin, J	1
King, S; Superko, HR	1
de Vries, JP; Hoefer, IE; Hurks, R; Kerver, M; Moll, FL; Pasterkamp, G; Schoneveld, A; Tangelder, MJ; Vink, A	1
King, S; Momary, K; Superko, HR	1
Barber, MJ; Chasman, DI; Chatterjee, A; Hyde, CL; Krauss, RM; Li, X; Mangravite, LM; McCarty, CA; Nickerson, DA; Ridker, PM; Rieder, MJ; Rotter, JI; Smith, JD; Stephens, M; Wilke, RA; Williams, PT	1
Arai, H; Ito, F; Miyagi, N; Someya, T; Tamura, K; Ushiyama, T	1
Cairns, R; Cannon, CP; Michael Gibson, C; Nazer, B; Ray, KK	1
Watson, KE	1
Strandberg, TE	1
Berk, M; Henry, MJ; Jacka, FN; Kotowicz, MA; Nicholson, GC; Pasco, JA; Williams, LJ	1
Cannon, CP; Khera, AV; Qin, J; Rader, DJ; Wolfe, ML	1
Akishita, M; Eto, M; Iijima, K; Kahyo, T; Kano, MR; Ogawa, S; Ota, H; Ouchi, Y; Setou, M	1
Acharjee, S; Cannon, CP	1
Atanasova, P; Bełtowski, J; Chaldakov, GN; Chylińska-Kula, B; Jamroz-Wiśniewska, A; Wójcicka, G	1
Bangalore, S; Cannon, CP; Murphy, SA; Qin, J; Sloan, S	1
Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A	1
Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M	1
Cheng, KA; Cheng, Z; Ding, L; Fang, F; Fang, Q; Liu, Y; Shi, GP	1
Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C	1
Koh, KK; Quon, MJ; Sakuma, I	1
Doi, M; Fukushima, H; Hamada, M; Matsui, H; Mizuno, T; Nishio, K; Shida, Y; Shima, M; Sugimoto, M; Yoshioka, A	1
Wilke, RA	1
Betteridge, J	1
Ashour, S; Bahbouh, M; Khateeb, M	1
Braunwald, E; Cannon, CP; Morrow, DA; Nazer, B; Ray, KK; Scirica, B; Sloan, S	1
Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T	1
Asuphol, O; Chaiyakunapruk, N; Dhippayom, T; Jeanpeerapong, N; Poowaruttanawiwit, P	1
Caretta, G; Dei Cas, L; Della Pina, P; Gorga, E; Madureri, A; Raddino, R	1
Belo, VA; Gerlach, RF; Guimaraes, DA; Izidoro-Toledo, TC; Tanus-Santos, JE	1
Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA	1
D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE	1
Abela, GS; Durga, S; Huang, R; Janoudi, A; Tamhane, U; Vedre, A	1
Shi, J; Xue, Z	1
Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S	1
Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y	1
Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA	1
Azuma, Y; Fujita, T; Haruyama, Y; Ikeda, Y; Kumagai, Y; Maeda, K; Sugiyama, Y; Yamane, N; Yoshida, K	1
Atanassova, P; Bełtowski, J; Chaldakov, GN; Jamroz-Wiśniewska, A; Kula, W; Rusek, M	1
Ali, OF; Butrous, GS; Growcott, EJ; Wharton, J	1
Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN	1
Fullerton, DA; Meng, X; Reece, TB; Reppert, AE; Sadaria, MR; Weyant, MJ; Yu, JA	1
Braunwald, E; Cannon, CP; Grandin, EW; Jarolim, P; Morrow, DA; Murphy, SA; Ritterova, L	1
Funae, Y; Hikita, Y; Iwao, H; Izumi, Y; Kawamoto, Y; Kusakabe, H; Miura, K; Nakao, T; Shiota, M; Tanaka, M	1
Komatsu, T; Kunugita, F; Nakamura, M; Ozawa, M; Sato, Y; Tachibana, H	1
Luzak, B; Rywaniak, J; Stanczyk, L; Watala, C	1
Choudhury, RP; Iacob, AO	1
Bonaca, MP; Bui, AH; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS	1
Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US	1
Itoh, H; Mitsuishi, M; Miyashita, K; Muraki, A; Tamaki, M; Tanaka, K	1
Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K	1
Jin, J; Kim, BY; Kim, DE; Kim, EK; Kim, JS; Lee, DK; Lee, H; Park, EJ; Shin, IJ	1
Aukrust, P; Breland, UM; Hagelsteen, K; Halvorsen, B; Haraldsen, G; Hol, J; Kasprzycka, M; Otterdal, K; Pedersen, TM; Ranheim, T; Stang, E	1
Hirayama, A; Nagao, K; Tani, S	1
Erkoseoglu, I; Kadioglu, M; Kalyoncu, NI; Kesim, M; Muci, E; Okuyan, M; Yaris, E	1
Li, L; Nouraldeen, A; Wilson, AG	1
Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C	1
Clark, K; Galloway, S; Lam, V; Mamo, J; Pallebage-Gamarallage, M; Takechi, R	1
Bang, CN; Gislason, GH; Greve, AM; Køber, L; Torp-Pedersen, C; Wachtell, K	1
Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M	1
Cannon, CP; Gibson, CM; Murphy, SA; Nazer, B; Ray, KK	1
Rosenberg, JL	1
Huang, CF; Lo, WT; Peng, HJ; Shih, YL; Wu, CC; Wu, TC	1
Biro, S; Ikeda, Y; Kono, S; Otonari, T; Sasaki, J; Uchida, Y	1
Latorre, A; Madrid, I; Moscardó, A; Santos, MT; Vallés, J	1
Alawi, M; Arafat, T; Awwad, AA; Yacoub, M	1
Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y	1
Lee, CW; Park, SJ	1
Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE	1
Butterton, JR; Feng, HP; Gupta, S; Hulskotte, EG; O'Mara, E; van Zutven, MG; Wagner, JA; Xuan, F	1
Bare, LA; Devlin, JJ; Iakoubova, OA; Leahy, KJ; O'Sullivan, AK; Parthan, A; Weinstein, MC	1
Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C	1
Fukumoto, Y; Kudo, S; Liao, JK; Minami, T; Nochioka, K; Shiba, N; Shimokawa, H; Takai, Y; Tanaka, S; Williams, CL	1
Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR	1
Gitirana, LB; Machado, MN; Magalhães, CB; Melo, AC; Porto, LC; Ribeiro, ML; Santos, JC; Valença, SS; Zin, WA	1
Kang, S; Liu, XB; Liu, Y	1
Marrion, NV; Robertson, JD; Robinson, ES; Stuart, SA	1
Catapano, AL; Corrao, G; Ibrahim, B; Mancia, G; Merlino, L; Nicotra, F; Pasini, TS; Zambon, A	1
Bao, JQ; Fallon, JK; Higgins, JW; Ke, AB; Manro, JR; Smith, PC; Zamek-Gliszczynski, MJ	1
Aukrust, P; Holven, KB; Nenseter, MS; Ose, L	1
Duleba, AJ; Ortega, I; Sokalska, A; Stanley, SD; Villanueva, JA	1
Casiano, H; Crespo, MJ; Cruz, N; Hernandez, C; Quidgley, J; Rivera, K; Torres, H	1
Barroso, MV; Benjamim, CF; de Brito-Gitirana, L; Ferreira, TS; Lanzetti, M; Porto, LC; Rueff-Barroso, CR; Valença, SS	1
Cannon, CP; de Lemos, J; Guo, J; Lewis, EF; Mega, JL; O'Donoghue, ML; Rouleau, JL; Sabatine, MS; Sarma, A	1
Bátai-Konczos, A; Jemnitz, K; Kékesi, O; Kis, E; Szabó, K; Szabó, M; Veres, Z	1
Cao, YJ; Du, HP; Hu, LF; Li, J; Liu, CF; Liu, H; Wang, F; Wang, YL; Xu, R; Xu, Y; You, SJ	1
Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK	1
Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y	1
Bansal, A; Burkholder, G; Goepfert, PA; Kahan, SM; Overton, ET; Sterrett, S; Westfall, AO; Zajac, AJ	1
Assassi, AL; Auzerie, J; Gaudin, K; Hamon, T; Perovitch, P; Roy, CE	1
Cannon, CP; Khera, AV; Murphy, SA; Qamar, A; Rader, DJ; Sabatine, MS	1
Chu, LX; He, LP; Liang, ZS; Mo, CG; Qin, YQ; Wang, XD; Xie, J; Yang, F; Zhou, SX	1
Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W	1
Dymkowska, D; Wrzosek, A; Zabłocki, K	1
Abrahamsson, B; Agrawal, R; Bergenholm, L; Björkbom, A; Bright, J; Cavallin, A; Gopaul, VS; Hammarberg, M; Hawthorne, G; Hurt-Camejo, E; Jansson-Löfmark, R; Jarke, A; Johansson, MJ; Li, X; Lundborg, E; Pieterman, EJ; Princen, HMG; Svensson, L	1

Reviews

72 review(s) available for pyrroles and pravastatin

Article	Year
Comparison of statins in hypertriglyceridemia. The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides	1998
Peripheral neuropathy and lipid-lowering therapy. Southern medical journal, 1998, Volume: 91, Issue:7 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin	1998
Maximizing the cost-effectiveness of lipid-lowering therapy. Archives of internal medicine, 1998, Oct-12, Volume: 158, Issue:18 Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin	1998
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney international. Supplement, 1999, Volume: 71 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta	1999
[The hyperlipidemias. Role of various statins]. Presse medicale (Paris, France : 1983), 1999, Nov-20, Volume: 28, Issue:36 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin	1999
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis, 2000, Volume: 149, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome	2000
Cholesterol lowering in atherosclerosis. The American journal of cardiology, 2000, Aug-24, Volume: 86, Issue:4B Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin	2000
Statin trials in progress: unanswered questions. Current atherosclerosis reports, 2001, Volume: 3, Issue:1 Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin	2001
New statins and new doses of older statins. Current atherosclerosis reports, 2001, Volume: 3, Issue:1 Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2001
Effective use of statins to prevent coronary heart disease. American family physician, 2001, Jan-15, Volume: 63, Issue:2 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin	2001
Statin therapy--what now? Drug and therapeutics bulletin, 2001, Volume: 39, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome	2001
A clinical focus on statins. Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:3 Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin	2001
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). European journal of clinical pharmacology, 2001, Volume: 57, Issue:5 Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin	2001
Managing dyslipidemia in the high-risk patient. The American journal of cardiology, 2002, Mar-07, Volume: 89, Issue:5A Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States	2002
Benefits and menaces related to the use of statins in patients after renal transplantation. Annals of transplantation, 2002, Volume: 7, Issue:2 Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin	2002
Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 41, Issue:3 Suppl 1 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Renal Dialysis; Simvastatin	2003
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Archives of internal medicine, 2003, Mar-24, Volume: 163, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome	2003
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Treating dyslipidemia with statins: the risk-benefit profile. American heart journal, 2003, Volume: 145, Issue:3 Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States	2003
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm. Current opinion in lipidology, 2003, Volume: 14, Issue:6 Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome	2003
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy. Circulation journal : official journal of the Japanese Circulation Society, 2004, Volume: 68, Issue:2 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States	2004
[Interactions of statins with antithrombotic drugs]. Medizinische Klinik (Munich, Germany : 1983), 2004, Feb-15, Volume: 99, Issue:2 Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Controlled Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Primary Prevention; Pyrroles; Rats; Ticlopidine; Time Factors	2004
[LDL cholesterol in normal range. The lower the better? Implications of the GREACE study]. MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Placebos; Pravastatin; Pyrroles; Risk Factors; Simvastatin	2003
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease]. Herz, 2004, Volume: 29, Issue:1 Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2004
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC family practice, 2003, Dec-01, Volume: 4 Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2003
The next step in cardiovascular protection. Atherosclerosis. Supplements, 2003, Volume: 4, Issue:5 Topics: Angina, Unstable; Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention	2003
[Ezetimibe: from pharmacology to clinical trials]. Annales d'endocrinologie, 2003, Volume: 64, Issue:6 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome	2003
Rosuvastatin-induced arrest in progression of renal disease. Cardiology, 2004, Volume: 102, Issue:1 Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials. Expert opinion on investigational drugs, 2004, Volume: 13, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2004
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Current opinion in lipidology, 2004, Volume: 15, Issue:6 Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes	2004
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal? The Canadian journal of cardiology, 2005, Volume: 21, Issue:1 Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Maximum Tolerated Dose; Practice Guidelines as Topic; Pravastatin; Prognosis; Pyrroles; Quebec; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome	2005
Atorvastatin. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic	2005
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? The American journal of cardiology, 2005, Sep-05, Volume: 96, Issue:5A Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2005
Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. The American journal of cardiology, 2005, Sep-05, Volume: 96, Issue:5A Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2005
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a Biomedical chromatography : BMC, 2006, Volume: 20, Issue:3 Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. Pharmacotherapy, 2005, Volume: 25, Issue:10 Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin	2005
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Preventive cardiology, 2005,Fall, Volume: 8, Issue:4 Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2005
Stroke prevention, blood cholesterol and statins. Acta neurologica Taiwanica, 2005, Volume: 14, Issue:3 Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Factors; Stroke	2005
In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits. Chest, 2005, Volume: 128, Issue:5 Topics: Angina, Unstable; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Ischemia; Pravastatin; Pyrroles; Syndrome; Treatment Outcome	2005
Statins and osteoporosis: new role for old drugs. The Journal of pharmacy and pharmacology, 2006, Volume: 58, Issue:1 Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. American heart journal, 2006, Volume: 151, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutic Equivalency; Treatment Outcome	2006
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:2 Pt 1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors	2006
The fading of reported effectiveness. A meta-analysis of randomised controlled trials. BMC medical research methodology, 2006, May-11, Volume: 6 Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Heptanoic Acids; Humans; Intraocular Pressure; Latanoprost; Pravastatin; Prostaglandins F, Synthetic; Publication Bias; Pyrroles; Randomized Controlled Trials as Topic; Sample Size; Selection Bias; Time Factors; Timolol; Treatment Outcome	2006
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology, 2006, Jun-06, Volume: 47, Issue:11 Topics: Acute Disease; Atorvastatin; Cardiac Output, Low; Coronary Disease; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Natriuretic Peptide, Brain; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome	2006
Statins: beneficial or adverse for glucose metabolism. Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:3 Topics: Atorvastatin; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles	2006
The year in non-ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology, 2006, Jul-18, Volume: 48, Issue:2 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Prognosis; Pyrroles; Risk Assessment; Stents; Syndrome; Thrombolytic Therapy; Ticlopidine	2006
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin	2006
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. Journal of the National Cancer Institute, 2006, Nov-01, Volume: 98, Issue:21 Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States	2006
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? The American journal of cardiology, 2006, Dec-04, Volume: 98, Issue:11A Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles	2006
Molecular basis of differences among statins and a comparison with antioxidant vitamins. The American journal of cardiology, 2006, Dec-04, Volume: 98, Issue:11A Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrroles; Vitamins	2006
Impact of statin dosing intensity on transaminase and creatine kinase. The American journal of medicine, 2007, Volume: 120, Issue:8 Topics: Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Transaminases	2007
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:10 Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides	2007
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. Journal of interventional cardiology, 2007, Volume: 20, Issue:6 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional	2007
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis. The American journal of cardiology, 2008, Feb-01, Volume: 101, Issue:3 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics	2008
Adjunctive interventions in myocardial infarction: the role of statin therapy. Current atherosclerosis reports, 2008, Volume: 10, Issue:2 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic	2008
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Reviews on recent clinical trials, 2006, Volume: 1, Issue:2 Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac	2008
[Pleiotropic effects of statins]. Revista medica de Chile, 2008, Volume: 136, Issue:6 Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2008
Statins: under investigation for increasing bone mineral density and augmenting fracture healing. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Animals; Atorvastatin; Bone Density; Bone Morphogenetic Protein 2; Clinical Trials as Topic; Fracture Healing; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 9; Osteoclasts; Pravastatin; Pyrroles; Simvastatin; Vascular Endothelial Growth Factor A	2008
Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies. Biomedical chromatography : BMC, 2009, Volume: 23, Issue:1 Topics: Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Indoles; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine	2009
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. Journal of the American College of Cardiology, 2008, Nov-25, Volume: 52, Issue:22 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Confidence Intervals; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk	2008
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. The pharmacogenomics journal, 2010, Volume: 10, Issue:1 Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
Lipid-lowering drugs and heart failure: where do we go after the statin trials? Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides	2010
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers. Critical pathways in cardiology, 2010, Volume: 9, Issue:3 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States	2010
Differential metabolic effects of distinct statins. Atherosclerosis, 2011, Volume: 215, Issue:1 Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. The pharmacogenomics journal, 2011, Volume: 11, Issue:3 Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome	2011
Pitavastatin - results from phase III & IV. Atherosclerosis. Supplements, 2010, Volume: 11, Issue:3 Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin	2010
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin]. Giornale italiano di cardiologia (2006), 2010, Volume: 11, Issue:10 Suppl 1 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention	2010
Targeting HDL-cholesterol to reduce residual cardiovascular risk. Current opinion in lipidology, 2012, Volume: 23, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2012
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult	2013

Trials

141 trial(s) available for pyrroles and pravastatin

Article	Year
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis, 1997, Volume: 130, Issue:1-2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides	1997
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) The American journal of cardiology, 1998, Mar-01, Volume: 81, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome	1998
Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia. The Netherlands journal of medicine, 1998, Volume: 52, Issue:4 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides	1998
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clinical pharmacology and therapeutics, 1999, Volume: 66, Issue:2 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Beverages; Citrus; Cross-Over Studies; Female; Gas Chromatography-Mass Spectrometry; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Reference Values; Volunteers	1999
Lowering effects of four different statins on serum triglyceride level. European journal of clinical pharmacology, 1999, Volume: 55, Issue:7 Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides	1999
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease. Transplantation proceedings, 2000, Volume: 32, Issue:2 Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides	2000
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. The American journal of cardiology, 2000, Jul-01, Volume: 86, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Margarine; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Sitosterols; Treatment Outcome; Triglycerides	2000
Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2000, Volume: 19, Issue:7 Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Creatine Kinase; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Triglycerides	2000
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clinical pharmacology and therapeutics, 2000, Volume: 68, Issue:4 Topics: Adult; Anticholesteremic Agents; Antifungal Agents; Area Under Curve; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Pravastatin; Pyridines; Pyrroles; Reference Values; Time Factors	2000
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thrombosis and haemostasis, 2001, Volume: 85, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome	2001
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes, obesity & metabolism, 2000, Volume: 2, Issue:6 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides	2000
Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. American heart journal, 2001, Volume: 141, Issue:3 Topics: Atorvastatin; Carotid Artery, Common; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Tunica Intima; Tunica Media	2001
Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis, 2001, Volume: 155, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin	2001
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 2001, Apr-17, Volume: 103, Issue:15 Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Pravastatin; Pyrroles; Receptors, Interleukin-6; Simvastatin; Treatment Outcome; Triglycerides	2001
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. Pharmacotherapy, 2001, Volume: 21, Issue:4 Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome	2001
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. American heart journal, 2001, Volume: 141, Issue:5 Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed	2001
The effect of pravastatin and atorvastatin on coenzyme Q10. American heart journal, 2001, Volume: 142, Issue:2 Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Coenzymes; Coronary Disease; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Reference Values; Triglycerides; Ubiquinone	2001
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. The American journal of medicine, 2001, Aug-15, Volume: 111, Issue:3 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pravastatin; Pyrroles; Risk; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; United States	2001
Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:12 Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Triglycerides	2001
Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. Journal of clinical pharmacology, 2002, Volume: 42, Issue:2 Topics: Adult; Area Under Curve; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Everolimus; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Mass Spectrometry; Middle Aged; Pravastatin; Pyrroles; Sirolimus	2002
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (London, England), 2002, Mar-08, Volume: 16, Issue:4 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; HIV Seronegativity; Human Experimentation; Humans; Pravastatin; Pyrroles; Ritonavir; Saquinavir; Simvastatin	2002
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. Journal of cardiovascular risk, 2002, Volume: 9, Issue:1 Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors	2002
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2001, Volume: 11, Issue:6 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin; Thrombin; Treatment Outcome	2001
Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels. Lipids, 2002, Volume: 37, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin	2002
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis, 2002, Volume: 164, Issue:2 Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome	2002
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation, 2002, Oct-15, Volume: 106, Issue:16 Topics: Adult; Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography	2002
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation, 2003, Jan-07, Volume: 107, Issue:1 Topics: Adolescent; Adult; Atorvastatin; Breath Tests; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine	2003
Time-dependent effect of statins on platelet function in hypercholesterolaemia. European journal of clinical investigation, 2002, Volume: 32, Issue:12 Topics: Adult; Analysis of Variance; Antiporters; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pravastatin; Pyrroles; Simvastatin; Time Factors	2002
Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia. Clinical science (London, England : 1979), 2003, Volume: 104, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol; Cross-Sectional Studies; Double-Blind Method; E-Selectin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Vascular Cell Adhesion Molecule-1	2003
Effect of atorvastatin and pravastatin on serum C-reactive protein. American heart journal, 2003, Volume: 145, Issue:2 Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Arteries; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima	2003
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. The American journal of cardiology, 2003, Mar-06, Volume: 91, Issue:5A Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2003
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS). PharmacoEconomics, 2003, Volume: 21 Suppl 1 Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome	2003
LIFE and ARBITER. Preventive cardiology, 2003,Spring, Volume: 6, Issue:2 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome	2003
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). The American journal of cardiology, 2003, Jul-15, Volume: 92, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors	2003
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin]. Kardiologiia, 2003, Volume: 43, Issue:1 Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors	2003
[Non ST elevation acute coronary syndrome: early use of pravastatin or atorvastatin is associated with divergent changes of parameters of hemostasis]. Kardiologiia, 2003, Volume: 43, Issue:6 Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Electrocardiography; Female; Heptanoic Acids; Homeostasis; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Syndrome; Time Factors	2003
Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circulation journal : official journal of the Japanese Circulation Society, 2003, Volume: 67, Issue:10 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles	2003
Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection. The American journal of cardiology, 2003, Nov-15, Volume: 92, Issue:10 Topics: Aged; Atorvastatin; C-Reactive Protein; Carotid Arteries; Carotid Artery Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Pravastatin; Pyrroles; Tunica Intima; Tunica Media	2003
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Current medical research and opinion, 2003, Volume: 19, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2003
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. The American journal of cardiology, 2004, Jan-01, Volume: 93, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides	2004
Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis. Clinical cardiology, 2004, Volume: 27, Issue:1 Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography	2004
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004, Mar-03, Volume: 291, Issue:9 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Observer Variation; Pravastatin; Pyrroles; Ultrasonography, Interventional	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles	2004
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation, 2004, Mar-23, Volume: 109, Issue:11 Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome	2004
Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. British journal of clinical pharmacology, 2004, Volume: 57, Issue:4 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Beverages; Citrus; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Male; Pravastatin; Pyrroles	2004
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. American heart journal, 2004, Volume: 147, Issue:4 Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2004
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease]. Revue medicale de Liege, 2004, Volume: 59, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic	2004
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. The American journal of cardiology, 2004, Nov-01, Volume: 94, Issue:9 Topics: Adolescent; Adult; Anticholesteremic Agents; Antiprotozoal Agents; Area Under Curve; Atorvastatin; Biomarkers; Calcium Channel Blockers; Clarithromycin; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mibefradil; Middle Aged; Pravastatin; Protein Synthesis Inhibitors; Pyrroles; Simvastatin; Verapamil	2004
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clinical therapeutics, 2004, Volume: 26, Issue:9 Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2004
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Magnetic resonance imaging, 2004, Volume: 22, Issue:9 Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin	2004
C-reactive protein levels and outcomes after statin therapy. The New England journal of medicine, 2005, Jan-06, Volume: 352, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Risk Factors; Secondary Prevention	2005
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. The New England journal of medicine, 2005, Jan-06, Volume: 352, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional	2005
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. Journal of atherosclerosis and thrombosis, 2004, Volume: 11, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein Lipase; Middle Aged; Pravastatin; Pyrroles	2004
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. The American journal of cardiology, 2005, Feb-01, Volume: 95, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2005
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2005, Volume: 12, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2005
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. International journal of cardiology, 2005, Apr-20, Volume: 100, Issue:2 Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2005
Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2005, Volume: 15, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Particle Size; Pravastatin; Pyrroles; Treatment Outcome; Triglycerides	2005
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:5 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides	2005
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clinic proceedings, 2005, Volume: 80, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin	2005
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. Journal of the American College of Cardiology, 2005, May-17, Volume: 45, Issue:10 Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome	2005
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). The American journal of cardiology, 2005, Jun-01, Volume: 95, Issue:11 Topics: Adolescent; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2005
Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. Journal of the American College of Cardiology, 2005, Jun-21, Volume: 45, Issue:12 Topics: Aged; Atorvastatin; Coronary Stenosis; Drug Administration Schedule; Echocardiography, Three-Dimensional; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Reproducibility of Results; Ultrasonography, Interventional	2005
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. Journal of acquired immune deficiency syndromes (1999), 2005, Jul-01, Volume: 39, Issue:3 Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin	2005
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2005, Volume: 5, Issue:9 Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pravastatin; Pyrroles; Simvastatin; Tacrolimus; Time Factors	2005
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin. International journal of cardiology, 2005, Oct-10, Volume: 104, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides	2005
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology, 2005, Oct-18, Volume: 46, Issue:8 Topics: Acute Disease; Angina, Unstable; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; Time Factors	2005
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology, 2005, Oct-18, Volume: 46, Issue:8 Topics: Acute Disease; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors; Syndrome	2005
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). The American journal of cardiology, 2005, Nov-01, Volume: 96, Issue:9 Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Syndrome; Ultrasonography; Vasodilation	2005
Achieving lipid goals in real life: the Dutch DISCOVERY study. International journal of clinical practice, 2005, Volume: 59, Issue:12 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides	2005
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery. The Annals of thoracic surgery, 2006, Volume: 81, Issue:1 Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T	2006
The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients. International journal of clinical pharmacology and therapeutics, 2005, Volume: 43, Issue:12 Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin; Thiobarbituric Acid Reactive Substances	2005
Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial. Atherosclerosis, 2006, Volume: 189, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional	2006
[Erythrocyte fluidity in patients with hyperlipidemia during statins therapy]. Polskie Archiwum Medycyny Wewnetrznej, 2005, Volume: 113, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Statistics, Nonparametric; Triglycerides	2005
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Circulation, 2006, Apr-11, Volume: 113, Issue:14 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Disease; Atorvastatin; Coronary Disease; Double-Blind Method; Enzymes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Pyrroles; Survival Analysis; Syndrome; Thrombolytic Therapy; Treatment Outcome	2006
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). The American journal of cardiology, 2006, Jun-01, Volume: 97, Issue:11 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors	2006
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation, 2006, Jun-20, Volume: 113, Issue:24 Topics: Adaptation, Physiological; Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Models, Cardiovascular; Pravastatin; Prospective Studies; Pyrroles; Risk Factors; Single-Blind Method; Triglycerides; Ultrasonography, Interventional; Vasculitis	2006
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. Journal of thrombosis and thrombolysis, 2006, Volume: 22, Issue:1 Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke	2006
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare? Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:3 Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment. Atherosclerosis, 2007, Volume: 194, Issue:1 Topics: Acute Disease; Aged; Angina, Unstable; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherectomy, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Glycophorins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Male; Middle Aged; Pravastatin; Pyrroles	2007
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. The American journal of cardiology, 2007, Feb-01, Volume: 99, Issue:3 Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Prosthesis Failure; Pyrroles; Stents; Ticlopidine; Treatment Outcome	2007
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation, 2007, Feb-13, Volume: 115, Issue:6 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pravastatin; Pyrroles; Sex Characteristics	2007
Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocrine journal, 2007, Volume: 54, Issue:3 Topics: Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hypercholesterolemia; Insulin-Secreting Cells; Japan; Patient Compliance; Pravastatin; Pyrroles	2007
[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia]. Przeglad lekarski, 2006, Volume: 63, Issue:9 Topics: Adult; Aged; Antioxidants; Atorvastatin; Catalase; Dyslipidemias; Erythrocyte Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome	2006
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation, 2007, Jun-19, Volume: 115, Issue:24 Topics: Acute Disease; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Artery Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Monocytes; Neopterin; Pravastatin; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Survival Analysis	2007
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2007,Summer, Volume: 14, Issue:2 Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2007
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. Journal of the American College of Cardiology, 2007, Jul-24, Volume: 50, Issue:4 Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine	2007
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). The American journal of cardiology, 2007, Oct-01, Volume: 100, Issue:7 Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine	2007
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free radical biology & medicine, 2007, Nov-01, Volume: 43, Issue:9 Topics: Anticholesteremic Agents; Arginine; Atherosclerosis; Atorvastatin; Cross-Sectional Studies; Dinoprost; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic	2007
[The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting]. Zhonghua xin xue guan bing za zhi, 2007, Volume: 35, Issue:9 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine	2007
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial American heart journal, 2008, Volume: 155, Issue:1 Topics: Acute Coronary Syndrome; Aged; Anti-Infective Agents; Atorvastatin; Biomarkers; Calgranulin A; Calgranulin B; Case-Control Studies; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Probability; Pyrroles; Reference Values; Risk Assessment; Survival Rate; Thrombolytic Therapy; Treatment Outcome	2008
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. American heart journal, 2008, Volume: 155, Issue:2 Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Atrial Fibrillation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Thrombolytic Therapy; Tirofiban; Tyrosine	2008
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology, 2008, Jan-29, Volume: 51, Issue:4 Topics: Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Treatment Outcome	2008
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology, 2008, Feb-19, Volume: 51, Issue:7 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides	2008
Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients. Ultrasound in medicine & biology, 2008, Volume: 34, Issue:9 Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Stenosis; Cholesterol; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-18; Interleukin-6; Male; Middle Aged; Pravastatin; Probability; Prospective Studies; Pyrroles; Simvastatin; Triglycerides; Tunica Intima; Ultrasonography	2008
Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. European journal of internal medicine, 2008, Volume: 19, Issue:3 Topics: Aged; Atorvastatin; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides	2008
Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clinical and experimental pharmacology & physiology, 2008, Volume: 35, Issue:9 Topics: Adipokines; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Cross-Over Studies; Female; Glucose Intolerance; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Pravastatin; Pyrroles	2008
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. Journal of the American College of Cardiology, 2008, Apr-29, Volume: 51, Issue:17 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Male; Middle Aged; Oxidative Stress; Phospholipids; Pravastatin; Pyrroles; Surveys and Questionnaires; Time Factors; Treatment Outcome	2008
Use of lipid-modulating drugs in complicated course of coronary heart disease. Bulletin of experimental biology and medicine, 2007, Volume: 144, Issue:3 Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Peptide Hydrolases; Pravastatin; Prothrombin; Pyrroles; Simvastatin; von Willebrand Factor	2007
HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation. Transplant immunology, 2008, Volume: 19, Issue:2 Topics: Adult; Aged; Atorvastatin; Cross-Sectional Studies; Down-Regulation; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin alpha4; Leukocyte Count; Male; Middle Aged; Monocytes; Pravastatin; Pyrroles; Receptors, IgG; Up-Regulation	2008
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). The American journal of cardiology, 2008, Sep-01, Volume: 102, Issue:5 Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine	2008
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. Journal of the American College of Cardiology, 2008, Sep-09, Volume: 52, Issue:11 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Pravastatin; Pyrroles; Treatment Outcome	2008
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Current HIV research, 2008, Volume: 6, Issue:6 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load	2008
Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circulation journal : official journal of the Japanese Circulation Society, 2009, Volume: 73, Issue:2 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Cross-Over Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Leukocytes; Male; Pravastatin; Pyrroles; Quinolines; rac1 GTP-Binding Protein; ras Proteins; Rats; Rats, Inbred WKY; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction	2009
Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease. Clinical science (London, England : 1979), 2009, May-01, Volume: 116, Issue:11 Topics: Anticholesteremic Agents; Atorvastatin; Cell Count; Cells, Cultured; Cholesterol; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Stem Cells; Telomere	2009
[Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina]. Zhonghua xin xue guan bing za zhi, 2008, Volume: 36, Issue:9 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine	2008
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:3 Topics: Acute Coronary Syndrome; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Time Factors; Treatment Outcome	2009
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism: clinical and experimental, 2009, Volume: 58, Issue:2 Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE The American journal of cardiology, 2009, Apr-15, Volume: 103, Issue:8 Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Seasons	2009
Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. European journal of clinical investigation, 2009, Volume: 39, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; MicroRNAs; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Single-Blind Method; Statistics as Topic; Stem Cells	2009
Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study. Journal of cardiology, 2009, Volume: 54, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Prospective Studies; Pyrroles; Research Design	2009
Identification of genetic variants associated with response to statin therapy. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:9 Topics: Acute Coronary Syndrome; Apolipoproteins E; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Cholesterol, LDL; Haplotypes; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Phenotype; Polymorphism, Genetic; Practice Guidelines as Topic; Pravastatin; Pyrroles; Treatment Outcome	2009
The SLCO1B15 genetic variant is associated with statin-induced side effects. Journal of the American College of Cardiology, 2009, Oct-20, Volume: 54, Issue:17* Topics: Aged; Atorvastatin; Creatine Kinase; Female; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin	2009
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I Journal of the American College of Cardiology, 2009, Dec-08, Volume: 54, Issue:24 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles	2009
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circulation. Cardiovascular genetics, 2008, Volume: 1, Issue:2 Topics: Adolescent; Adult; Aged; Alleles; Anticholesteremic Agents; Apolipoprotein E3; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Regression Analysis; Simvastatin	2008
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T Journal of the American College of Cardiology, 2009, Dec-15, Volume: 54, Issue:25 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke	2009
[Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial]. Zhonghua yi xue za zhi, 2009, Aug-25, Volume: 89, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Ticlopidine; Time; Treatment Outcome; Young Adult	2009
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial). The American journal of cardiology, 2010, Mar-01, Volume: 105, Issue:5 Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Risk Factors; Stroke; Treatment Outcome	2010
Genome-wide association of lipid-lowering response to statins in combined study populations. PloS one, 2010, Mar-22, Volume: 5, Issue:3 Topics: Adult; Aged; Atorvastatin; Bayes Theorem; Cholesterol; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin	2010
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. Journal of thrombosis and thrombolysis, 2010, Volume: 30, Issue:1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Observation; Pravastatin; Pyrroles; Treatment Outcome	2010
On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). The American journal of cardiology, 2010, Aug-15, Volume: 106, Issue:4 Topics: Acute Coronary Syndrome; Atorvastatin; C-Reactive Protein; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Factors; Triglycerides	2010
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TI Circulation, 2010, Nov-23, Volume: 122, Issue:21 Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Proportional Hazards Models; Pyrroles; Risk Factors; Thrombolytic Therapy; Treatment Outcome	2010
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients. Journal of atherosclerosis and thrombosis, 2011, Volume: 18, Issue:2 Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke	2011
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. European heart journal, 2011, Volume: 32, Issue:11 Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Neopterin; Pravastatin; Proportional Hazards Models; Pyrroles; Sensitivity and Specificity; Treatment Outcome	2011
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circulation. Cardiovascular quality and outcomes, 2011, Volume: 4, Issue:3 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome	2011
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR American heart journal, 2011, Volume: 161, Issue:6 Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment	2011
Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease. Heart and vessels, 2012, Volume: 27, Issue:4 Topics: Aged; Analysis of Variance; Angiogenic Proteins; Angiopoietin-2; Atorvastatin; Biomarkers; Coronary Artery Disease; Down-Regulation; Female; Hepatocyte Growth Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Leptin; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A	2012
Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:4 Topics: Adult; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Liver; Male; Metabolic Clearance Rate; Midazolam; Organic Anion Transporters; Pravastatin; Pyrroles; Time Factors; Young Adult	2011
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:2 Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Placenta Growth Factor; Pravastatin; Pregnancy Proteins; Pyrroles; Risk Factors	2012
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. European heart journal, 2012, Volume: 33, Issue:17 Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine	2012
Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Oct-01, Volume: 12, Issue:5 Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocyte Count; Lipids; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Pravastatin; Pyrroles; Regression Analysis; Risk Factors	2012
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:3 Topics: Acute Coronary Syndrome; Aged; Albuminuria; Anticholesteremic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors	2013
Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study. Journal of atherosclerosis and thrombosis, 2013, Volume: 20, Issue:4 Topics: Adult; Atorvastatin; Blood Glucose; Cholesterol, HDL; Dyslipidemias; Female; Glucose; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postmenopause; Pravastatin; Pyrroles; Young Adult	2013
Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2013, Feb-15, Volume: 917-918 Topics: Administration, Oral; Amlodipine; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Combinations; Drug Stability; Heptanoic Acids; Humans; Isomerism; Linear Models; Pravastatin; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Therapeutic Equivalency	2013
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning). Journal of the American College of Cardiology, 2013, May-14, Volume: 61, Issue:19 Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification	2013
Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome. PharmacoEconomics, 2013, Volume: 31, Issue:6 Topics: Acute Coronary Syndrome; Atorvastatin; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Genetic Testing; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Markov Chains; Middle Aged; Molecular Targeted Therapy; Pravastatin; Pyrroles; Quality-Adjusted Life Years	2013
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Atorvastatin; Biomarkers; Cardiomegaly; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Vessels; Cross-Over Studies; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanine Nucleotide Exchange Factors; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Mice; Mice, Knockout; Neuropeptides; Oxidative Stress; Phosphatidylinositol 3-Kinase; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RNA Interference; Signal Transduction; Transfection	2013
The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. Journal of the American Heart Association, 2014, May-01, Volume: 3, Issue:3 Topics: Acute Coronary Syndrome; Acute Kidney Injury; Atorvastatin; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pravastatin; Pyrroles	2014
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists]. MMW Fortschritte der Medizin, 2014, Dec-15, Volume: 156, Issue:21-22 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin	2014
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). The American journal of cardiology, 2015, Sep-01, Volume: 116, Issue:5 Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Leptin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Pyrroles; Recurrence; Resistin; Retrospective Studies; Risk Factors; Survival Rate; Thrombolytic Therapy; United States	2015

Other Studies

278 other study(ies) available for pyrroles and pravastatin

Article	Year
Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochimica et biophysica acta, 1992, Jan-24, Volume: 1123, Issue:2 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Unsaturated; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tissue Distribution	1992
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase. Biochemical and biophysical research communications, 1990, Jul-31, Volume: 170, Issue:2 Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured	1990
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis, 1996, Jan-26, Volume: 119, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin	1996
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. The American journal of cardiology, 1997, Jul-01, Volume: 80, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Pravastatin; Pyrroles; Simvastatin	1997
Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacological research, 1997, Volume: 36, Issue:2 Topics: Animals; Apoptosis; Atorvastatin; Carotid Stenosis; Cell Division; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Rabbits; Simvastatin	1997
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) The American journal of cardiology, 1998, Aug-01, Volume: 82, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	1998
Cost-effectiveness of statins. The American journal of cardiology, 1998, Dec-01, Volume: 82, Issue:11 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin	1998
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. American heart journal, 1999, Volume: 138, Issue:1 Pt 1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome	1999
Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney international. Supplement, 1999, Volume: 71 Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Protein Prenylation; Pyrroles; Rats; Simvastatin	1999
Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. Journal of cardiovascular pharmacology, 1999, Volume: 34, Issue:1 Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Calcium; Cells, Cultured; Chelating Agents; Dose-Response Relationship, Drug; Drug Interactions; Fura-2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; Muscle Contraction; Muscle, Smooth, Vascular; Phenylephrine; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstrictor Agents	1999
[Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1999, Volume: 114 Suppl 1 Topics: Adenosine Triphosphate; Animals; Atorvastatin; Dogs; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pravastatin; Pyridines; Pyrroles; Simvastatin	1999
Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arteriosclerosis, thrombosis, and vascular biology, 2000, Volume: 20, Issue:1 Topics: Animals; Aorta, Thoracic; Atorvastatin; Base Sequence; Botulinum Toxins; DNA Primers; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phorbol 12,13-Dibutyrate; Pravastatin; Protein Kinase C; Pyridines; Pyrroles; Rats; Rats, Wistar; Superoxide Dismutase; Superoxides; Vasodilation	2000
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2000, Volume: 52, Issue:2 Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity	2000
Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis, 2000, Volume: 152, Issue:1 Topics: Apoptosis; Atorvastatin; Cell Survival; Cells, Cultured; Coronary Vessels; Cytokines; Dose-Response Relationship, Drug; Endothelium, Vascular; Fas Ligand Protein; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Glycoproteins; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Reference Values; Sensitivity and Specificity; Simvastatin	2000
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. The American journal of cardiology, 2000, Nov-15, Volume: 86, Issue:10 Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors	2000
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. The American journal of cardiology, 2000, Dec-01, Volume: 86, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires	2000
Statins as a newly recognized type of immunomodulator. Nature medicine, 2000, Volume: 6, Issue:12 Topics: Adjuvants, Immunologic; Anticholesteremic Agents; Atorvastatin; Endothelium, Vascular; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Lovastatin; Lymphocyte Activation; Macrophages; Monocytes; Nuclear Proteins; Pravastatin; Pyrroles; Saphenous Vein; T-Lymphocytes; Trans-Activators	2000
Statins early in acute coronary syndromes. International journal of clinical practice, 2000, Volume: 54, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Treatment Outcome	2000
Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin. American journal of physiology. Heart and circulatory physiology, 2001, Volume: 280, Issue:6 Topics: Administration, Oral; Animals; Animals, Newborn; Atorvastatin; Blood Pressure; Body Weight; DNA; Heart; Heart Rate; Heart Ventricles; Heptanoic Acids; Mitogen-Activated Protein Kinases; Myocardium; Organ Size; Pravastatin; Proteins; Pyrroles; RNA; Simvastatin; Swine; Water	2001
Statin induced myopathy does not show up in MIBI scintigraphy. Nuclear medicine communications, 2001, Volume: 22, Issue:5 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi	2001
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels. International journal of clinical practice, 2001, Volume: 55, Issue:4 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Models, Economic; Pravastatin; Pyridines; Pyrroles; Simvastatin	2001
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharmaceutical research, 2001, Volume: 18, Issue:6 Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin	2001
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. Journal of atherosclerosis and thrombosis, 2000, Volume: 7, Issue:3 Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin	2000
Effect of statins on bone mineral density and bone histomorphometry in rodents. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:10 Topics: Animals; Atorvastatin; Bone Density; Bone Development; Bone Resorption; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ovariectomy; Pravastatin; Pyrroles; Radiography; Rats; Rats, Sprague-Dawley; Simvastatin	2001
Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2001, Volume: 121, Issue:10 Topics: Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Diltiazem; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley	2001
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation, 2001, Oct-30, Volume: 104, Issue:18 Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency	2001
Managed care trends in statin usage. Managed care (Langhorne, Pa.), 2001, Volume: 10, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States	2001
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis, 2001, Volume: 159, Issue:1 Topics: Animals; Aorta; Arteries; Arteriosclerosis; Atorvastatin; Carotid Arteries; Chemokine CCL2; Cholesterol; Coronary Vessels; Down-Regulation; Femoral Artery; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pravastatin; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine	2001
Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines. Circulation, 2001, Nov-27, Volume: 104, Issue:22 Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Follow-Up Studies; Heptanoic Acids; Humans; Japan; Male; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States	2001
The use over time of statins in coronary patients in an Italian tertiary referral center. Italian heart journal : official journal of the Italian Federation of Cardiology, 2001, Volume: 2, Issue:11 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Utilization Review; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin	2001
Safety and efficacy of atorvastatin in heart transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2002, Volume: 21, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glucocorticoids; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Prednisone; Pyrroles; Retrospective Studies; Treatment Outcome	2002
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. The American journal of cardiology, 2002, Apr-01, Volume: 89, Issue:7 Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design	2002
Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study. Current medical research and opinion, 2001, Volume: 17, Issue:4 Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome	2001
Interaction between ritonavir and statins. The American journal of medicine, 2002, Apr-15, Volume: 112, Issue:6 Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Ritonavir; Simvastatin	2002
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:8 Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin	2002
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less? Circulation, 2002, Oct-15, Volume: 106, Issue:16 Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography	2002
The lower the LDL, the better. Circulation, 2002, Oct-15, Volume: 106, Issue:16 Topics: Academies and Institutes; Atorvastatin; Heptanoic Acids; Human Experimentation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insurance Coverage; Insurance, Health; Lipoproteins, LDL; Pravastatin; Pyrroles	2002
Zeroing in on how low cholesterol should go. Heart advisor, 2002, Volume: 5, Issue:11 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Risk Factors	2002
Statins regulate alpha2beta1-integrin expression and collagen I-dependent functions in human vascular smooth muscle cells. Journal of cardiovascular pharmacology, 2003, Volume: 41, Issue:1 Topics: Animals; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemotaxis; Collagen Type I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin alpha2beta1; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Rats; Reverse Transcriptase Polymerase Chain Reaction	2003
Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. The American journal of medicine, 2002, Dec-01, Volume: 113, Issue:8 Topics: Aged; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Observer Variation; Patient Compliance; Pravastatin; Probability; Prospective Studies; Pyrroles; Reference Values; Simvastatin; Treatment Failure; Treatment Outcome	2002
Statin-induced myositis migrans. Wiener klinische Wochenschrift, 2002, Nov-30, Volume: 114, Issue:21-22 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors	2002
Muscular adverse effects of statins. Prescrire international, 2003, Volume: 12, Issue:63 Topics: Anticholesteremic Agents; Fatty Acids, Monounsaturated; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin	2003
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. PharmacoEconomics, 2003, Volume: 21 Suppl 1 Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Models, Economic; Pravastatin; Pyrroles; Simvastatin; United Kingdom	2003
Variable influence of statins on isoprostanes in hyperlipidemia. Advances in experimental medicine and biology, 2003, Volume: 525 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking	2003
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes care, 2003, Volume: 26, Issue:6 Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States	2003
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?]. MMW Fortschritte der Medizin, 2003, May-22, Volume: 145, Issue:21 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors	2003
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins. Acta cardiologica, 2003, Volume: 58, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies	2003
Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins. Prescrire international, 2003, Volume: 12, Issue:66 Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Evaluation; Heptanoic Acids; Humans; Hypertension; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin; Stroke; Treatment Outcome	2003
Prevention of nitrate tolerance by long-term treatment with statins. Cardiovascular drugs and therapy, 2003, Volume: 17, Issue:2 Topics: Administration, Oral; Animals; Aorta, Thoracic; Atorvastatin; Down-Regulation; Drug Administration Schedule; Drug Tolerance; Guanylate Cyclase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Injections, Subcutaneous; Luminescent Measurements; Male; NADH, NADPH Oxidoreductases; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitroglycerin; Pravastatin; Pyrroles; Rats; Rats, Wistar; Superoxides; Vasodilator Agents	2003
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovascular research, 2003, Sep-01, Volume: 59, Issue:3 Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors	2003
Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biological & pharmaceutical bulletin, 2003, Volume: 26, Issue:12 Topics: Administration, Oral; Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Glucose; Glucose Tolerance Test; Heptanoic Acids; Injections, Intravenous; Insulin; Insulin Secretion; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Streptozocin; Time Factors	2003
Statin face-off. Surprises from the first head-to-head comparison. Time, 2003, Nov-24, Volume: 162, Issue:21 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Treatment Outcome; United States	2003
Effect of statins on the progression of bioprosthetic aortic valve degeneration. The American journal of cardiology, 2003, Dec-15, Volume: 92, Issue:12 Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography	2003
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. BioFactors (Oxford, England), 2003, Volume: 18, Issue:1-4 Topics: Antioxidants; Atorvastatin; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Erythrocytes; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphocytes; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Ubiquinone; Vitamin E	2003
Aggressive lipid-lowering regimen halts CHD progression. Geriatrics, 2004, Volume: 59, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic	2004
[First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis]. MMW Fortschritte der Medizin, 2003, Dec-18, Volume: 145, Issue:51-52 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Time Factors; Ultrasonography, Interventional	2003
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go? Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:6 Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke	2004
Is there a "best" statin drug? The Johns Hopkins medical letter health after 50, 2004, Volume: 15, Issue:11 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
Toward a role for statins in immunomodulation. Molecular interventions, 2002, Volume: 2, Issue:8 Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Autoimmune Diseases; Cytokines; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin	2002
High-intensity statin treatment for coronary heart disease. JAMA, 2004, Mar-03, Volume: 291, Issue:9 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Dropouts; Pravastatin; Pyrroles; Risk Factors; Ultrasonography, Interventional	2004
Is Lipitor better than Pravachol? Health news (Waltham, Mass.), 2004, Volume: 10, Issue:1 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles	2004
Intensive statin therapy--a sea change in cardiovascular prevention. The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15 Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles	2004
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Medical hypotheses, 2004, Volume: 62, Issue:4 Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin	2004
What to do about cholesterol now. Here's the take-home message from startling new research findings. Heart advisor, 2004, Volume: 7, Issue:1 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomedical Research; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles	2004
Lipitor bests Pravachol at certain doses. Health news (Waltham, Mass.), 2004, Volume: 10, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention	2004
Cholesterol: low is good. Lower is better. PROVE IT has doctors rethinking how to treat high cholesterol and what's a good target. Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:9 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values	2004
Cholesterol limbo: How low should the bar go. Ratcheting down LDL to extra-low levels with high-dose statins seems to work wonders. Harvard health letter, 2004, Volume: 29, Issue:7 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Reference Values	2004
Clopidogrel-atorvastatin interaction. Circulation, 2004, May-25, Volume: 109, Issue:20 Topics: Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Heptanoic Acids; Humans; Platelet Aggregation Inhibitors; Pravastatin; Prodrugs; Pyrroles; Ticlopidine	2004
Believe-it then PROVE-IT. International journal of clinical practice, 2004, Volume: 58, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Reference Values	2004
Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochemical pharmacology, 2004, Jun-15, Volume: 67, Issue:12 Topics: Adult; Annexin A5; Apoptosis; Atorvastatin; Caspase 3; Caspases; Cholesterol; Enzyme Inhibitors; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin	2004
"Major surprise" in a new study means likely changes in treatment. Heart advisor, 2004, Volume: 7, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values	2004
[Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high]. MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13 Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Risk; Survival Analysis; Survival Rate	2004
[Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis]. MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Ultrasonography, Interventional	2004
[Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)]. MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2004
Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively. The American journal of cardiology, 2004, Jul-01, Volume: 94, Issue:1 Topics: Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukins; Male; Matrix Metalloproteinases; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Tissue Inhibitor of Metalloproteinases; Tumor Necrosis Factor-alpha; Ultrasonography	2004
New LDL goals: even lower? The Johns Hopkins medical letter health after 50, 2004, Volume: 17, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Secondary Prevention	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles	2004
Battle of the statins, or how the news media can change patient care. JAAPA : official journal of the American Academy of Physician Assistants, 2004, Volume: 17, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Media; Practice Patterns, Physicians'; Pravastatin; Pyrroles	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Dropouts; Pravastatin; Pyrroles	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Triglycerides	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles	2004
Updated guidelines support even lower cholesterol levels for at-risk patients. Report on medical guidelines & outcomes research, 2004, Aug-06, Volume: 15, Issue:15 Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors; Risk Reduction Behavior; Simvastatin; Triglycerides; United States	2004
[Statin therapy in patients with acute coronary syndrome. "Prove-it" study]. Der Internist, 2004, Volume: 45, Issue:12 Topics: Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Treatment Outcome	2004
[Endothelial dysfunction, inflammation and statins: new evidences]. Revista espanola de cardiologia, 2004, Volume: 57, Issue:10 Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Circulation; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Interleukin-6; Pravastatin; Pyrroles; Rabbits; Time Factors	2004
[Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)]. MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Approval; Drugs, Generic; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles	2004
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003. Atherosclerosis. Supplements, 2004, Volume: 5, Issue:3 Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
[Lowering of cholesterol. What role is played by the choice of statins?]. MMW Fortschritte der Medizin, 2004, Sep-02, Volume: 146, Issue:35-36 Topics: Adult; Age Factors; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Time Factors	2004
How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke. Health news (Waltham, Mass.), 2004, Volume: 10, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke	2004
Statin-associated exacerbation of myasthenia gravis. Neurology, 2004, Dec-14, Volume: 63, Issue:11 Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone	2004
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE). American heart journal, 2004, Volume: 148, Issue:6 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Pravastatin; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design	2004
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. Journal of clinical pharmacy and therapeutics, 2005, Volume: 30, Issue:1 Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration	2005
What did PROVE-IT prove? Diabetes technology & therapeutics, 2004, Volume: 6, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Diabetic Angiopathies; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results; Thrombolytic Therapy	2004
Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings. Life sciences, 2005, Feb-25, Volume: 76, Issue:15 Topics: Animals; Aorta, Thoracic; Atorvastatin; Endothelium, Vascular; Glyburide; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Nitroarginine; Ouabain; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Wistar; Vasodilation	2005
PROVE IT then believe it. International journal of clinical practice, 2005, Volume: 59, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles	2005
Intensive versus moderate lipid lowering with statins in acute coronary syndromes. Current atherosclerosis reports, 2005, Volume: 7, Issue:2 Topics: Adolescent; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hyperlipidemias; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome	2005
Reversal of atherosclerosis with aggressive lipid lowering. Current atherosclerosis reports, 2005, Volume: 7, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hyperlipidemias; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2005
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug safety, 2005, Volume: 28, Issue:3 Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors	2005
Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug. World journal of gastroenterology, 2005, Feb-21, Volume: 11, Issue:7 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileal Diseases; Ileum; Indoles; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Ulcer	2005
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets, 2004, Volume: 15, Issue:8 Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine	2004
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:6 Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Phosphorylation; Pravastatin; Protein Prenylation; Pyrroles; RNA, Messenger; Simvastatin; STAT3 Transcription Factor	2005
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, Apr-26, Volume: 172, Issue:9 Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis	2005
Adverse events with concomitant amiodarone and statin therapy. Preventive cardiology, 2005,Spring, Volume: 8, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Aged; Amiodarone; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Simvastatin; United States; United States Food and Drug Administration	2005
Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS. Journal of managed care pharmacy : JMCP, 2005, Volume: 11, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles	2005
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits]. Arquivos brasileiros de cardiologia, 2005, Volume: 84, Issue:4 Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin	2005
[The PROVE IT-TIMI-22 study or the biter being bit]. Revue medicale suisse, 2005, Apr-06, Volume: 1, Issue:14 Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles	2005
Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry. Journal of pharmaceutical and biomedical analysis, 2005, Sep-15, Volume: 39, Issue:3-4 Topics: Apoptosis; Atorvastatin; Avidin; Biotin; Cell Line; Cell Separation; Cells, Cultured; Drug Industry; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia; Microscopy, Fluorescence; Necrosis; Pharmaceutical Preparations; Pravastatin; Propidium; Pyridines; Pyrroles; Simvastatin; Time Factors	2005
Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial. Bone, 2005, Volume: 37, Issue:2 Topics: Atorvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic	2005
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides	2005
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B15, SLCO1B115 and SLCO1B115+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and genomics, 2005, Volume: 15, Issue:7* Topics: Alleles; Atorvastatin; Biological Transport; Cells, Cultured; Genetic Variation; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver-Specific Organic Anion Transporter 1; Mutagenesis, Site-Directed; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Substrate Specificity; Transfection	2005
Intensive lipid lowering with atorvastatin in coronary disease. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk	2005
Acute onset and worsening of diabetes concurrent with administration of statins. Endocrine journal, 2005, Volume: 52, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles	2005
Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. Journal of atherosclerosis and thrombosis, 2005, Volume: 12, Issue:3 Topics: 3T3-L1 Cells; Animals; Atorvastatin; Cell Culture Techniques; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Mevalonic Acid; Mice; Pioglitazone; PPAR gamma; Pravastatin; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Thiazolidinediones	2005
Statin use after acute myocardial infarction: a nationwide study in Denmark. British journal of clinical pharmacology, 2005, Volume: 60, Issue:2 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Atorvastatin; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Population Surveillance; Pravastatin; Pyrroles; Registries; Sex Distribution; Simvastatin	2005
In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clinical immunology (Orlando, Fla.), 2005, Volume: 117, Issue:1 Topics: Atorvastatin; Cell Proliferation; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes, Mononuclear; Lovastatin; Mitogens; Pravastatin; Pyrroles; Simvastatin	2005
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells. The Journal of surgical research, 2005, Volume: 129, Issue:1 Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin	2005
REVERSAL and PROVE-IT: are clinically oriented trials really better than "pure" scientific studies? International journal of cardiology, 2005, Sep-01, Volume: 103, Issue:3 Topics: Atorvastatin; Coronary Artery Disease; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Outcome Assessment, Health Care; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic	2005
Not all statins interfere with clopidogrel during antiplatelet therapy. European journal of clinical investigation, 2005, Volume: 35, Issue:8 Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine	2005
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thrombosis and haemostasis, 2005, Volume: 94, Issue:2 Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol, LDL; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine; Time Factors; Wound Healing	2005
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. Circulation, 2005, Aug-30, Volume: 112, Issue:9 Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Utilization; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Thrombolytic Therapy	2005
Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry, 2005, Sep-06, Volume: 44, Issue:35 Topics: Atorvastatin; Binding Sites; Calorimetry; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Protein Binding; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thermodynamics	2005
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly]. MMW Fortschritte der Medizin, 2005, Aug-18, Volume: 147, Issue:33-34 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors	2005
New light on statin side effects. What recent research on the cholesterol drugs means to you. Heart advisor, 2005, Volume: 8, Issue:8 Topics: Atorvastatin; Biomedical Research; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2005
Differences between statins on clinical endpoints: a population-based cohort study. Current medical research and opinion, 2005, Volume: 21, Issue:9 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome	2005
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. Journal of the American College of Cardiology, 2005, Oct-18, Volume: 46, Issue:8 Topics: Acute Disease; Angina, Unstable; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome	2005
How common is rhabdomyolysis in patients receiving lipid-lowering therapy? Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:3 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Creatine Kinase; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States	2005
Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages. Experimental and molecular pathology, 2006, Volume: 80, Issue:2 Topics: Animals; Atorvastatin; Cell Proliferation; Concanavalin A; Heptanoic Acids; Lectins; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microspheres; Mitogens; Phagocytosis; Pravastatin; Pyrroles; Simvastatin; Spleen	2006
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biological & pharmaceutical bulletin, 2005, Volume: 28, Issue:11 Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Simvastatin	2005
Differential associations of statin and fibrate treatment with carotid arterial remodeling. American journal of hypertension, 2005, Volume: 18, Issue:11 Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography	2005
[How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition]. MMW Fortschritte der Medizin, 2005, Nov-10, Volume: 147, Issue:45 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors	2005
Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. The American journal of medicine, 2005, Volume: 118 Suppl 12A Topics: Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Infections; Male; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2005
Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study). The American journal of cardiology, 2005, Dec-15, Volume: 96, Issue:12 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Ultrasonography, Interventional	2005
Statins for high-risk patients without heart disease or high cholesterol. The Medical letter on drugs and therapeutics, 2006, Jan-02, Volume: 48, Issue:1225 Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke	2006
Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplantation proceedings, 2005, Volume: 37, Issue:9 Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Middle Aged; Overweight; Pravastatin; Pyrroles; Retrospective Studies; Safety	2005
Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro. Pharmacology, 2006, Volume: 76, Issue:3 Topics: Animals; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Pravastatin; Pyrroles; Serotonin; Simvastatin; Swine; Time Factors; Vasoconstriction	2006
Muscle symptoms associated with statins: a series of twenty patients. Basic & clinical pharmacology & toxicology, 2006, Volume: 98, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pravastatin; Pyrroles; Simvastatin	2006
C-reactive protein levels and outcomes after statin therapy. Current atherosclerosis reports, 2006, Volume: 8, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors	2006
Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:2 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carbohydrate Metabolism; Diabetes Mellitus; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Pravastatin; Pyrroles; Retrospective Studies; Treatment Outcome	2006
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. American heart journal, 2006, Volume: 151, Issue:3 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin	2006
Effect of statin treatment on coronary collateral development in patients with diabetes mellitus. The American journal of cardiology, 2006, Mar-15, Volume: 97, Issue:6 Topics: Angina Pectoris; Atorvastatin; Cholesterol, LDL; Collateral Circulation; Coronary Angiography; Coronary Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin	2006
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation, 2006, Mar-21, Volume: 113, Issue:11 Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine	2006
Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochemical pharmacology, 2006, Apr-28, Volume: 71, Issue:9 Topics: Adult; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Cells, Cultured; DNA Fragmentation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Myocytes, Cardiac; Neoplasm Proteins; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin	2006
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression. Circulation, 2006, Mar-21, Volume: 113, Issue:11 Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States	2006
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. Journal of the American Geriatrics Society, 2006, Volume: 54, Issue:3 Topics: Age Factors; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Prescriptions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Myocardial Infarction; Odds Ratio; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Survival Rate; Treatment Outcome	2006
Statins and stroke: current clinical practice. Stroke, 2006, Volume: 37, Issue:5 Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke	2006
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:2 Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies	2006
Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells. Experimental biology and medicine (Maywood, N.J.), 2006, Volume: 231, Issue:6 Topics: Animals; Aorta; Atorvastatin; Cells, Cultured; Endothelial Cells; Endothelin-1; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Pyridines; Pyrroles; Quinolines; RNA, Messenger; Swine	2006
Effects of preoperative statin therapy on cytokines after cardiac surgery. The Thoracic and cardiovascular surgeon, 2006, Volume: 54, Issue:4 Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Heart Arrest, Induced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-10; Interleukin-6; Male; Postoperative Complications; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors	2006
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2006, Volume: 6, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain	2006
Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive care medicine, 2006, Volume: 32, Issue:8 Topics: Atorvastatin; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multiple Organ Failure; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Survival Rate	2006
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. The Journal of pathology, 2006, Volume: 210, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Animals; Annexins; Anticholesteremic Agents; Atorvastatin; Biomarkers; Calcium Channels, L-Type; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Receptors, LDL; Simvastatin	2006
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke, 2006, Volume: 37, Issue:8 Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin	2006
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data. American heart journal, 2006, Volume: 152, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin	2006
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?]. MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional	2006
[For coronary disease patients is certain: the lower the LDL the better]. MMW Fortschritte der Medizin, 2006, Jun-15, Volume: 148, Issue:24 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Odds Ratio; Pravastatin; Pyrroles; Simvastatin; Time Factors; Treatment Outcome	2006
Clopidogrel-statin interaction: a mountain or a mole hill? American heart journal, 2006, Volume: 152, Issue:2 Topics: Atorvastatin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine	2006
Pleiotropic effects of statins and early benefit in the PROVE IT-TIMI-22 study. Journal of the American College of Cardiology, 2006, Aug-15, Volume: 48, Issue:4 Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Endpoint Determination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results	2006
Statins and cerebral vasomotor reactivity: implications for a new therapy? Stroke, 2006, Volume: 37, Issue:10 Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial	2006
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urologic nursing, 2006, Volume: 26, Issue:4 Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis	2006
Toxicity of statins on rat skeletal muscle mitochondria. Cellular and molecular life sciences : CMLS, 2006, Volume: 63, Issue:19-20 Topics: Animals; Apoptosis; Atorvastatin; Cytochromes c; DNA Fragmentation; Fatty Acids; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potentials; Mitochondria, Muscle; Mitochondrial Membranes; Muscle, Skeletal; Oxygen; Pravastatin; Pyridines; Pyrroles; Rats; Simvastatin	2006
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn-Schmiedeberg's archives of pharmacology, 2006, Volume: 374, Issue:3 Topics: Acetylcholine; Animals; Apoptosis; Atorvastatin; Caspase 3; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Nitroprusside; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Ventricular Pressure	2006
Impact of high dose statin trials on hospital prescribers. European journal of clinical pharmacology, 2007, Volume: 63, Issue:1 Topics: Aged; Atorvastatin; Cohort Studies; Coronary Disease; Databases, Factual; Drug Prescriptions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Patient Discharge; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic	2007
Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Molecular cancer therapeutics, 2006, Volume: 5, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinoma, Hepatocellular; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Etoposide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Morpholines; Phosphorylation; Pravastatin; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53	2006
The MEGA study. Lancet (London, England), 2006, Dec-09, Volume: 368, Issue:9552 Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2006
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:1 Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left	2007
Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. Journal of atherosclerosis and thrombosis, 2006, Volume: 13, Issue:6 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; Simvastatin; Sterol Regulatory Element Binding Protein 1	2006
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). The American journal of cardiology, 2007, Feb-01, Volume: 99, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration	2007
Statin therapy and the elderly: SAGE advice? Circulation, 2007, Feb-13, Volume: 115, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Pyrroles	2007
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart (British Cardiac Society), 2007, Volume: 93, Issue:8 Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome	2007
Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line. Journal of cardiovascular pharmacology, 2007, Volume: 49, Issue:5 Topics: Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blotting, Western; Cell Line; Cell Proliferation; Cell Survival; Constitutive Androstane Receptor; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Endothelial Cells; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Glucocorticoid; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saphenous Vein; Transcription Factors; Up-Regulation	2007
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids in health and disease, 2007, Jun-13, Volume: 6 Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2007
Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle & nerve, 2007, Volume: 36, Issue:3 Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin	2007
Effect of statin withdrawal on frequency of cardiac events after vascular surgery. The American journal of cardiology, 2007, Jul-15, Volume: 100, Issue:2 Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures	2007
P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:10 Topics: Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Brain; Heptanoic Acids; Lactones; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Pravastatin; Pyrroles; Simvastatin	2007
Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts. Clinical and experimental pharmacology & physiology, 2007, Volume: 34, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Caspase 3; Cell Line; Clofibrate; DNA Fragmentation; Drug Synergism; Enzyme Activation; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Pravastatin; Pyridines; Pyrroles	2007
On the factors modulating the effect of statins on malignant cell proliferation. Cancer investigation, 2007, Volume: 25, Issue:5 Topics: Annexin A5; Atorvastatin; Cell Division; Cell Line, Tumor; DNA Fragmentation; DNA, Neoplasm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; K562 Cells; Kinetics; Lovastatin; Pravastatin; Pyrroles; Simvastatin	2007
Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2008, Volume: 62, Issue:1 Topics: Adult; Apoptosis; Atorvastatin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes; Lovastatin; Male; Middle Aged; Phagocytes; Phagocytosis; Pravastatin; Pyrroles; Simvastatin	2008
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis, 2008, Volume: 197, Issue:2 Topics: Adult; Animals; Atorvastatin; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; T-Lymphocytes, Regulatory; Up-Regulation	2008
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. The American journal of geriatric pharmacotherapy, 2007, Volume: 5, Issue:3 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2007
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:4 Topics: Atorvastatin; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pyrroles; Saphenous Vein; Simvastatin	2007
Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. BMC clinical pharmacology, 2007, Dec-05, Volume: 7 Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases, Factual; Drug Administration Schedule; Drug Prescriptions; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Norway; Patient Selection; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Sex Factors; Simvastatin; Tablets	2007
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:3 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Child; Child, Preschool; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Infant; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Rhabdomyolysis; Simvastatin; United States; United States Food and Drug Administration	2008
Lowering LDL-C for optimal protection in high-risk patients. The American journal of managed care, 2008, Volume: 14, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Guideline Adherence; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Assessment	2008
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis. American heart journal, 2008, Volume: 155, Issue:2 Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome	2008
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. The American journal of cardiology, 2008, Feb-01, Volume: 101, Issue:3 Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2008, Apr-23, Volume: 33, Issue:4-5 Topics: Acids; Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Lactones; Microscopy, Fluorescence; Molecular Structure; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Satellite Cells, Skeletal Muscle; Simvastatin; Structure-Activity Relationship	2008
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products. Journal of pharmaceutical and biomedical analysis, 2008, Jul-15, Volume: 47, Issue:3 Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization	2008
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:5 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States	2008
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:2 Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides	2008
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS patient care and STDs, 2008, Volume: 22, Issue:6 Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome	2008
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. Journal of pharmacological sciences, 2008, Volume: 107, Issue:1 Topics: 3T3-L1 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; ADP Ribose Transferases; Amides; Animals; Atorvastatin; Botulinum Toxins; Dose-Response Relationship, Drug; Glucose; Glucose Transporter Type 4; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Receptor Substrate Proteins; Mice; Phosphorylation; Polyisoprenyl Phosphates; Pravastatin; Protein Kinase Inhibitors; Protein Prenylation; Protein Transport; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; rab4 GTP-Binding Proteins; Receptor, Insulin; rho GTP-Binding Proteins; rho-Associated Kinases; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction	2008
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:3 Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides	2008
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression. The Journal of invasive cardiology, 2008, Volume: 20, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional	2008
Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. Journal of the American College of Cardiology, 2008, Jul-01, Volume: 52, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Coronary Angiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoprotein(a); Male; Malondialdehyde; Middle Aged; Oxidative Stress; Phospholipids; Pravastatin; Prospective Studies; Pyrroles; Research Design	2008
Lipid management: considerations in acute coronary syndrome. Current cardiology reports, 2008, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Triglycerides	2008
Lipophilicity and cardiovascular outcome in patients with CHF. American heart journal, 2008, Volume: 156, Issue:2 Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2008
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective. Clinical therapeutics, 2008, Volume: 30, Issue:7 Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2008
Ptosis, diplopia and statins: an association? European journal of neurology, 2008, Volume: 15, Issue:10 Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus	2008
Impact of adherence to statins on chronic heart failure in primary prevention. British journal of clinical pharmacology, 2008, Volume: 66, Issue:5 Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2008
Statins alone are ineffective in cerebral malaria but potentiate artesunate. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11 Topics: Animals; Antimalarials; Artemisinins; Artesunate; Atorvastatin; Disease Models, Animal; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Malaria, Cerebral; Malaria, Falciparum; Mice; Neuroprotective Agents; Pravastatin; Pyrroles; Simvastatin	2008
Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects? Journal of leukocyte biology, 2009, Volume: 85, Issue:1 Topics: Atorvastatin; Cells, Cultured; Chemotactic Factors; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Infiltration; Neutrophils; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; rhoA GTP-Binding Protein; Simvastatin	2009
The influence of statin medications on prostate-specific antigen levels. Journal of the National Cancer Institute, 2008, Nov-05, Volume: 100, Issue:21 Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans	2008
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. Journal of atherosclerosis and thrombosis, 2008, Volume: 15, Issue:5 Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies	2008
The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation. Transplantation proceedings, 2008, Volume: 40, Issue:9 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Drug Tolerance; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Lipids; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Young Adult	2008
Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation, 2008, Dec-27, Volume: 86, Issue:12 Topics: Adrenal Cortex Hormones; Aged; Atorvastatin; Cholesterol; Cyclosporine; Dyslipidemias; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Safety; Sirolimus; Treatment Outcome; Triglycerides	2008
[Statin therapy and muscle disorders]. Orvosi hetilap, 2009, Feb-08, Volume: 150, Issue:6 Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
[Comment from the cardiologic viewpoint]. Praxis, 2009, Feb-04, Volume: 98, Issue:3 Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2009, Feb-04, Volume: 11, Issue:2 Topics: Animals; Atorvastatin; Disease Models, Animal; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Simvastatin	2009
Preoperative statin use and infection after cardiac surgery: a cohort study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Apr-01, Volume: 48, Issue:7 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemoprevention; Cohort Studies; Female; Heptanoic Acids; Hospitals, University; Humans; Immunologic Factors; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Surgical Wound Infection; Thoracic Surgery; Treatment Outcome	2009
Potentiated cytotoxic effects of statins and ajoene in murine melanoma cells. Melanoma research, 2009, Volume: 19, Issue:2 Topics: Animals; Apoptosis; Atorvastatin; Cell Line, Tumor; Disulfides; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanocytes; Melanoma, Experimental; Mevalonic Acid; Mice; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; Sulfoxides; Terpenes	2009
Seasonal variation in lipids: should we consider it more? The American journal of cardiology, 2009, Sep-01, Volume: 104, Issue:5 Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Seasons	2009
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. British journal of clinical pharmacology, 2009, Volume: 68, Issue:3 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin	2009
Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease. Journal of atherosclerosis and thrombosis, 2010, Jul-30, Volume: 17, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Risk Factors; Triglycerides	2010
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach? Journal of the American College of Cardiology, 2009, Dec-15, Volume: 54, Issue:25 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; Endpoint Determination; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors	2009
Letter by Superko and King regarding article, "Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals". Circulation, 2010, Mar-09, Volume: 121, Issue:9 Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Genetic Predisposition to Disease; Goals; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinesins; Male; Middle Aged; Mutation, Missense; Patient Selection; Pravastatin; Pyrroles; Risk	2010
Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2010, Volume: 39, Issue:5 Topics: Aged; Aorta; Aortic Aneurysm, Abdominal; Atorvastatin; Biomarkers; Cathepsin A; Cathepsin B; Chi-Square Distribution; Cohort Studies; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukins; Lymphotoxin-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Netherlands; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Surgical Procedures	2010
Statins in acute coronary syndromes and genetic insight. Journal of the American College of Cardiology, 2010, Mar-23, Volume: 55, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Treatment Outcome	2010
Pravastatin treatment before coronary artery bypass grafting for reduction of postoperative atrial fibrillation. General thoracic and cardiovascular surgery, 2010, Volume: 58, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Disease-Free Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2010
Pitavastatin: the newest HMG-CoA reductase inhibitor. Reviews in cardiovascular medicine, 2010,Winter, Volume: 11, Issue:1 Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Product Surveillance, Postmarketing; Pyrroles; Quinolines; Simvastatin	2010
Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychotherapy and psychosomatics, 2010, Volume: 79, Issue:5 Topics: Aspirin; Atorvastatin; Case-Control Studies; Confidence Intervals; Cytokines; Depressive Disorder, Major; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Middle Aged; Models, Psychological; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors	2010
Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:11 Topics: Animals; Atorvastatin; Catalase; Cellular Senescence; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sirtuin 1; Umbilical Veins	2010
Differential effects of statins on endogenous H2S formation in perivascular adipose tissue. Pharmacological research, 2011, Volume: 63, Issue:1 Topics: Adipose Tissue; Animals; Aorta, Thoracic; Atorvastatin; Cholesterol; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Hydrogen Sulfide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; KATP Channels; Liver; Male; Mitochondria, Liver; Oxidation-Reduction; Potassium Channel Blockers; Pravastatin; Pyrroles; Quinone Reductases; Rats; Rats, Wistar; Sulfides; Triglycerides; Ubiquinone; Vasoconstrictor Agents; Vasodilation	2011
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins]. Medicina clinica, 2011, Jun-25, Volume: 137, Issue:3 Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides	2011
Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:12 Topics: Alanine Transaminase; Alkaline Phosphatase; Atorvastatin; Cytochrome P-450 CYP3A; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Middle Aged; Pravastatin; Pyrroles	2010
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes. Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 1 Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions. Thrombosis and haemostasis, 2011, Volume: 105, Issue:2 Topics: Atorvastatin; Blood Platelets; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; P-Selectin; Perfusion; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Regional Blood Flow; Stress, Mechanical; Thrombin; Thromboplastin; Thrombosis; Time Factors; von Willebrand Factor	2011
A novel use of oxidative coupling reactions for determination of some statins (cholesterol-lowering drugs) in pharmaceutical formulations. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2011, Volume: 78, Issue:3 Topics: Atorvastatin; Chemistry, Pharmaceutical; Dosage Forms; Excipients; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Molecular Structure; Oxidation-Reduction; Oxidative Coupling; Pravastatin; Pyrroles; Spectrophotometry	2011
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia. Endocrine journal, 2011, Volume: 58, Issue:3 Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome	2011
Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand. The International journal of pharmacy practice, 2011, Volume: 19, Issue:2 Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Electronic Health Records; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Primary Prevention; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Thailand	2011
Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn-Schmiedeberg's archives of pharmacology, 2011, Volume: 383, Issue:6 Topics: Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pravastatin; Pyrroles; Simvastatin; Tetradecanoylphorbol Acetate; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Umbilical Veins	2011
Statins and prostate cancer diagnosis and grade in a veterans population. Journal of the National Cancer Institute, 2011, Jun-08, Volume: 103, Issue:11 Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans	2011
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. The American journal of cardiology, 2011, Jun-15, Volume: 107, Issue:12 Topics: Animals; Atorvastatin; Cholesterol; Crystallization; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Microscopy, Electron, Scanning; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Rabbits; Simvastatin	2011
[Retention behavior of statins in microemulsion liquid chromatography]. Se pu = Chinese journal of chromatography, 2011, Volume: 29, Issue:2 Topics: Atorvastatin; Chromatography, Liquid; Emulsions; Heptanoic Acids; Lovastatin; Models, Chemical; Pravastatin; Pyrroles; Simvastatin	2011
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients. The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2011
Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites. Atherosclerosis, 2011, Volume: 219, Issue:2 Topics: Adipokines; Adipose Tissue; Animals; Atorvastatin; Biomarkers; Blood Glucose; Calcifediol; Calcitriol; Cholecalciferol; Fasting; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycerol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Pravastatin; Pyrroles; Rats; Rats, Wistar; Time Factors	2011
Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells. Respiratory research, 2011, Oct-14, Volume: 12 Topics: Apoptosis; Atorvastatin; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Genetic Pleiotropy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pulmonary Artery; Pyrroles; Simvastatin	2011
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients. Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult	2011
Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. The Journal of thoracic and cardiovascular surgery, 2011, Volume: 142, Issue:5 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; NF-kappa B; Pravastatin; Pyrroles; Simvastatin	2011
Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clinical chemistry, 2012, Volume: 58, Issue:1 Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Female; Galectin 3; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors	2012
Pravastatin-induced proangiogenic effects depend upon extracellular FGF-2. Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:9 Topics: Angiogenesis Inducing Agents; Cell Movement; Cell Proliferation; Cells, Cultured; Fibroblast Growth Factor 2; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Fibroblast Growth Factor	2012
Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin. International heart journal, 2011, Volume: 52, Issue:6 Topics: Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Retrospective Studies; Secondary Prevention; Tachycardia, Paroxysmal; Time Factors; Treatment Outcome	2011
Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition. European journal of clinical investigation, 2012, Volume: 42, Issue:8 Topics: Adult; Aspirin; Atorvastatin; Blood Platelets; Cholesterol; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Young Adult	2012
Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. Journal of applied physiology (Bethesda, Md. : 1985), 2012, Volume: 113, Issue:3 Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Mitochondria, Muscle; Muscle Cells; Muscle Strength; Muscle, Skeletal; Organ Size; Oxygen Consumption; Physical Conditioning, Animal; Physical Endurance; Pravastatin; Pyrroles; Ubiquinone	2012
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice. Pharmacotherapy, 2012, Volume: 32, Issue:7 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2012, Volume: 30, Issue:3 Topics: Animals; Atorvastatin; Calcium; Cell Line; Cyclic AMP Response Element-Binding Protein; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Mice; Microglia; Phosphorylation; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; Signal Transduction; Simvastatin; Up-Regulation	2012
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies. PloS one, 2012, Volume: 7, Issue:7 Topics: Atorvastatin; Cell Compartmentation; Chemokine CXCL1; Chemokines; E-Selectin; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1beta; Intracellular Space; Multivesicular Bodies; Pravastatin; Prenylation; Pyrroles; Simvastatin; Solubility; Subcellular Fractions; Tetraspanin 30	2012
The evaluation of analgesic effects of simvastatin, pravastatin and atorvastatin in hot plate test. European review for medical and pharmacological sciences, 2012, Volume: 16, Issue:6 Topics: Analgesics; Animals; Atorvastatin; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred BALB C; Naloxone; NG-Nitroarginine Methyl Ester; Pravastatin; Pyrroles; Simvastatin	2012
Evaluation of transporter-mediated hepatic uptake in a non-radioactive high-throughput assay: a study of kinetics, species difference and plasma protein effect. Xenobiotica; the fate of foreign compounds in biological systems, 2013, Volume: 43, Issue:3 Topics: Animals; Atorvastatin; Biological Assay; Biological Transport; Blood Proteins; Cells, Cultured; Cryopreservation; Estrone; Female; Hepatocytes; Heptanoic Acids; High-Throughput Screening Assays; Humans; Kinetics; Liver; Male; Metformin; Organic Anion Transporters; Pravastatin; Pyrroles; Radioactivity; Reproducibility of Results; Species Specificity; Time Factors	2013
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PloS one, 2012, Volume: 7, Issue:8 Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration	2012
Restoration of dietary-fat induced blood-brain barrier dysfunction by anti-inflammatory lipid-modulating agents. Lipids in health and disease, 2012, Sep-17, Volume: 11 Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins B; Atorvastatin; Blood-Brain Barrier; Brain; Diet, High-Fat; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ibuprofen; Immunoglobulin G; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles	2012
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study. European journal of preventive cardiology, 2014, Volume: 21, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Comorbidity; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Polypharmacy; Pravastatin; Propensity Score; Proportional Hazards Models; Pyrroles; Registries; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Time Factors; Treatment Outcome	2014
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration. Scandinavian journal of public health, 2012, Volume: 40, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome	2012
Antilipid agents may provide allergy protection. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013, Volume: 110, Issue:1 Topics: Animals; Asthma; Atorvastatin; Bronchial Hyperreactivity; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypersensitivity; Pravastatin; Pyrroles	2013
Effect of oral administration with pravastatin and atorvastatin on airway hyperresponsiveness and allergic reactions in asthmatic mice. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2013, Volume: 110, Issue:1 Topics: Administration, Oral; Animals; Asthma; Atorvastatin; Bronchial Hyperreactivity; Cytokines; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypersensitivity; Immunoglobulin G; Mice; Mice, Inbred BALB C; Ovalbumin; Pravastatin; Pyrroles; Rats, Sprague-Dawley; Th1 Cells	2013
Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms. Thrombosis research, 2013, Volume: 131, Issue:4 Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Blood Platelets; Calcium; Collagen; Cyclooxygenase 1; Drug Combinations; Drug Synergism; Heptanoic Acids; Humans; Mitogen-Activated Protein Kinases; Phospholipase A2 Inhibitors; Phospholipases A2; Phosphorylation; Platelet Aggregation; Pravastatin; Pyrroles; Simvastatin; Thromboxane A2; Thromboxane-A Synthase	2013
Factors associated with statin selection among privately insured commercial and Medicare patients. Current medical research and opinion, 2013, Volume: 29, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult	2013
Statins for treating stable angina: can statins improve the plaque morphology and angina? Future cardiology, 2013, Volume: 9, Issue:2 Topics: Angina Pectoris; Angina, Stable; Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Ultrasonography, Interventional	2013
Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:6 Topics: Adolescent; Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Hepacivirus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proline; Protease Inhibitors; Pyrroles; Treatment Outcome; Young Adult	2013
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France. Applied health economics and health policy, 2013, Volume: 11, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2013
Risk of incident diabetes among patients treated with statins: population based study. BMJ (Clinical research ed.), 2013, May-23, Volume: 346 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2013
Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury. International immunopharmacology, 2013, Volume: 17, Issue:1 Topics: Animals; Atorvastatin; Biomarkers; Endotoxins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung Injury; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin	2013
Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory. PloS one, 2013, Volume: 8, Issue:9 Topics: Animals; Atorvastatin; Body Weight; Cholesterol; Cognition; Discrimination, Psychological; Heptanoic Acids; Male; Memory; Pravastatin; Pyrroles; Rats; Reversal Learning; Time Factors	2013
Long-term use of statins reduces the risk of hospitalization for dementia. Atherosclerosis, 2013, Volume: 230, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Dementia; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Italy; Logistic Models; Male; Middle Aged; Pravastatin; Pyrroles; Risk; Simvastatin; Time Factors	2013
Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Drug metabolism and disposition: the biological fate of chemicals, 2014, Volume: 42, Issue:1 Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Biological Availability; Heptanoic Acids; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Knockout; Middle Aged; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Pravastatin; Pyrroles; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Tissue Distribution; Young Adult	2014
Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy. Scandinavian journal of clinical and laboratory investigation, 2014, Volume: 74, Issue:1 Topics: Adult; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Cells, Cultured; Chemokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Inflammation Mediators; Leukocytes, Mononuclear; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Young Adult	2014
Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells. Biology of reproduction, 2014, Volume: 90, Issue:2 Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Female; Gonadal Steroid Hormones; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Metabolic Networks and Pathways; Ovary; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Theca Cells	2014
Daily administration of atorvastatin and simvastatin for one week improves cardiac function in type 1 diabetic rats. Pharmacology, 2014, Volume: 93, Issue:1-2 Topics: Animals; Atorvastatin; Blood Glucose; Cardiac Output; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Administration Schedule; Heart; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Ventricular Function, Left	2014
Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke. Inflammation, 2014, Volume: 37, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Inhalation Exposure; Lung; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides	2014
Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes. Toxicology in vitro : an international journal published in association with BIBRA, 2014, Volume: 28, Issue:6 Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Bilirubin; Biological Transport; Cell Culture Techniques; Cells, Cultured; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pravastatin; Pyrimidines; Pyrroles; Rats; Rosuvastatin Calcium; Sulfonamides	2014
Statins upregulate cystathionine γ-lyase transcription and H2S generation via activating Akt signaling in macrophage. Pharmacological research, 2014, Volume: 87 Topics: Animals; Atorvastatin; Cell Line; Cystathionine gamma-Lyase; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydrogen Sulfide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Macrophages; Mice; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; RNA, Messenger; Signal Transduction; Up-Regulation	2014
Statin use in Australian children: a retrospective audit of four pediatric hospitals. Paediatric drugs, 2014, Volume: 16, Issue:5 Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2014
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism: clinical and experimental, 2015, Volume: 64, Issue:4 Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2015
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients. AIDS (London, England), 2014, Nov-13, Volume: 28, Issue:17 Topics: Anti-Retroviral Agents; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; HIV Infections; HIV-1; Humans; Immunologic Factors; Interferon-gamma; Lymphocyte Activation; Pravastatin; Pyrroles; Retrospective Studies; T-Lymphocyte Subsets; T-Lymphocytes	2014
Green analytical method development for statin analysis. Journal of chromatography. A, 2015, Feb-06, Volume: 1380 Topics: Acetonitriles; Atorvastatin; Chromatography, High Pressure Liquid; Ethanol; Fatty Acids, Monounsaturated; Fluvastatin; Green Chemistry Technology; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Pyrroles; Solubility; Solvents	2015
Pravastatin and C reactive protein modulate protease- activated receptor-1 expression in vitro blood platelets. Cellular and molecular biology (Noisy-le-Grand, France), 2016, Feb-29, Volume: 62, Issue:2 Topics: Adenosine Diphosphate; Blood Platelets; C-Reactive Protein; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation; Humans; Immunoblotting; P-Selectin; Platelet Aggregation; Pravastatin; Pyrroles; Quinazolines; Receptor, PAR-1; Receptors, Thromboxane A2, Prostaglandin H2; Scavenger Receptors, Class E; Thrombin	2016
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type. International journal of environmental research and public health, 2020, 08-30, Volume: 17, Issue:17 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin	2020
Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells. Journal of applied toxicology : JAT, 2021, Volume: 41, Issue:7 Topics: Anticholesteremic Agents; Antioxidants; Atorvastatin; Cell Line; Cells, Cultured; Endothelial Cells; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitochondria; Nicotinamide N-Methyltransferase; Nitric Oxide; Pravastatin; Pyrroles; Reactive Oxygen Species	2021
Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2021, Jun-01, Volume: 161 Topics: Animals; Atorvastatin; Dogs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mineral Oil; Pravastatin; Pyrroles	2021